Azetidine derivatives for inducing autophagy and uses thereof

Abstract

The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer, tautomer or N-oxide thereof, which are suitable for inducing and / or stimulating the process of autophagy, as well as compounds of formula (I) for use in medicine and for use in the treatment of autophagy-related diseases.

Description

[0001] Attorney Docket No.063692-504001WO NOVEL COMPOUNDS FOR INDUCING AUTOPHAGY AND USES THEREOF RELATED APPLICATIONS This application claims priority to and the benefit of European Patent Application No. 24183018.1, filed on June 19, 2024, the entire contents of which is incorporated herein by reference for all purposes. FIELD OF THE INVENTION The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer, tautomer or N-oxide thereof, which are suitable for inducing and / or stimulating the process of autophagy, as well as compounds of formula (I) for use in medicine and for use in the treatment of autophagy-related diseases. BACKGROUND OF THE INVENTION Autophagy is the cell’s method for degradation of unnecessary or damaged components such as proteins, organelles and invading pathogens. It utilises an orchestrated process resulting in lysosomal degradation resulting in recycling of cellular components and maintenance of cellular homeostasis. The cell-autonomous antimicrobial defence functions of autophagy, demonstrated initially in the case of streptococci and Mycobacterium tuberculosis have been extended to a wide variety of microbes with a caveat that most highly adapted pathogens have evolved specific protective mechanisms against autophagic elimination of microbes. Other studies have uncovered orderly intersections between autophagy and innate and adaptive immunity, T cell development, differentiation and homeostasis, and inflammatory responses. Thus, autophagy plays a large role in various diseases such as cancer, inflammatory disease, degenerative neurological disease, and immune disease. Autophagy is a cell survival mechanism that is induced in stressed cells. Towers and Thorburn (Therapeutic Targeting of Autophagy. EBioMedicine. 2016;14:15- 23) disclose that autophagy is widely accepted as cytoprotective against neurodegenerative diseases and a variety of clinical interventions are moving forward to increase autophagy as a therapeutic intervention. Autophagy has both positive and negative roles in cancer and this has led to controversy over whether or how autophagy manipulation should be attempted in cancer therapy. Nevertheless, cancer is the disease where most current activity in trying to manipulate Attorney Docket No.063692-504001WO autophagy for therapy is taking place and dozens of clinical trials are using autophagy inhibition with Chloroquine or Hydroxychloroquine in combination with other drugs for the treatment of multiple neoplasms. They review recent literature implicating autophagy in neurodegenerative diseases and cancer and highlight some of the opportunities, controversies and potential pitfalls of therapeutically targeting autophagy. Mulcahy Levy and Thorburn (Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ 27, 543-857 (2020)) disclose that autophagy allows for cellular material to be delivered to lysosomes for degradation resulting in basal or stress-induced turnover of cell components that provide energy and macromolecular precursors. These activities are thought to be particularly important in cancer where both tumour-promoting and tumour-inhibiting functions of autophagy have been described. Autophagy has also been intricately linked to apoptosis and programmed cell death, and understanding these interactions is becoming increasingly important in improving cancer therapy and patient outcomes. In the review, they consider how recent discoveries about how autophagy manipulation elicits its effects on cancer cell behaviour can be leveraged to improve therapeutic responses. Grainger et al. (1995, Nature Medicine 1: 1067-1073) and Reckless et al. (1997, Circulation 95: 1542-1548) have demonstrated that tamoxifen, a potent inducer of autophagy, inhibited atherosclerosis in mice models by suppressing the diet-induced formation of lipid lesions in the aorta by lowering of low-density lipoprotein (LDL) cholesterol. Dikic and Elazar (Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol 201819(6):349-364) discuss that autophagy is deregulated in the context of various human pathologies, including cancer and neurodegeneration, and its modulation has considerable potential as a therapeutic approach. Pierzynowska et al. (Metab Brain Dis 2018; 33(4):989-1008) focuses on ways by which autophagy can be stimulated and discusses that activation of autophagy by different factors or processes can be considered as a therapeutic strategy in metabolic neurodegenerative diseases. The development of more selective autophagy inducers is needed for the treatment and / or prevention of diseases where autophagy plays a role. It is an object of the present invention to provide effective agents that can be used for the prevention and treatment of conditions and diseases that can be treated / prevented by inducing and / or stimulating autophagy, in particular cancer, age-related diseases, and infections. Attorney Docket No.063692-504001WO OBJECTS AND SUMMARY OF THE INVENTION It is therefore an object of the present invention to provide compounds, which induce and / or stimulate autophagy. It is another object of the present invention to provide compounds, which are suitable for use as a medicament. It is another object of the present invention to provide compounds, which are suitable for use in the treatment of an autophagy-related disease or condition, in particular cancer, age-related diseases, and infections. It is yet another object of the present invention to provide compounds, which are suitable for use in the treatment of one or more autophagy-related diseases is selected from the group consisting of neurodegenerative diseases, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, systemic lupus erythematosus, epilepsy, cancer, liver diseases (e.g. nonalcoholic fatty liver disease (NAFLD)), a1 antitrypsin deficiency, Charcot Marie Tooth syndrome, Rett Syndrome, Sickle Cell disease, Wilson Disease, amyloidosis, Gaucher’s diseases, lysosomal and glycogen storage disorders (e.g., Glycogen Storage Disease type 1A (GSD1A)), cystic fibrosis; viral infection and diseases human cytomegalovirus (HCMV) infection, hepatitis B, human immunodeficiency virus infection, Zika virus infection, coronavirus infection, HCoV-229E, HCoV-NL63, betacoronavirus infection, such as HCoV-OC43, SARS-CoV-1, HCoV-HKU1, MERS-CoV or SARS-CoV-2, bacterial infections, metabolic disorders, diabetes, fibrosis, silicosis, diabetic retinopathy, glaucoma, cataracts, age-related macular degeneration, glomerulonephritis, glomerulosclerosis, wound healing disorders, Niemann-Pick type C (NPC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), muscular dystrophy, Duchenne muscular dystrophy, Limb-girdle muscular dystrophy, myopathy, myofibrillar myopathy, hereditary myopathy, diabetic cardiomyopathy, anti-inflammatory disorders, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, irritable bowel syndrome, Crohn’s disease, vascular disorders, stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, Behcet’s syndrome, giant cell arteritis, polymyalgia rheumatic, Wegener’s granulomatosis, Churg-Strauss syndrome, vasculitis, Henoch-Schonlein pruprua, Kawasaki disease, viral infection or replication, pox virus infection, herpes virus infection, asthma, allergic rhinitis, COPD, osteoporosis, organ transplant rejection, psoriasis, hypertrophic scarring (keloid formation), adhesion formations following general or gynecological surgery, lung fibrosis, liver fibrosis, kidney fibrosis, disorders caused by intracellular parasites, malaria, tuberculosis, neuropathic pain, post-operative phantom limb pain or postherpetic neuralgia, allergies, amyotrophic lateral sclerosis (ALS), antigen induced recall response, immune response suppression, muscle degeneration and atrophy, frailty in aging, spinal cord injury, and diseases and conditions involving misfolded and / or nonfolded proteins. It is yet a further object of the Attorney Docket No.063692-504001WO present invention to provide compounds suitable for use for stimulating autophagy in an in-vitro assay. The above objects can be achieved by the compounds of formula (I) as defined herein as well as pharmaceutical compositions comprising the same, and by the medical uses thereof. The inventors of the present invention surprisingly found that the compounds of formula (I) as defined herein induce and / or stimulate autophagy. Accordingly, the compounds of formula (I) are for use in medicine, in particular for use in the treatment of an autophagy-related disease or condition, in particular cancer, age-related diseases, and infections. In a first aspect, the present invention therefore relates to a compound according to formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting of L is selected from the group consisting of Attorney Docket No.063692-504001WO X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3. In another aspect, the present invention relates to a compound according to formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein Attorney Docket No.063692-504001WO A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting of L is selected from the group consisting of X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, C1-C4-haloalkyl and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; Attorney Docket No.063692-504001WO RXis halogen, C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4- alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3. In a preferred embodiment, B is selected from the group consisting of In a more preferred embodiment, B In another preferred embodiment, L is selected from the group consisting of In a more preferred embodiment, L In another preferred embodiment, RNis H; R2, R3are independently of each other selected from H, and C1-C2-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or Attorney Docket No.063692-504001WO different substituents RX. In another preferred embodiment, A is a 5-membered fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9-membered fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX. In a further preferred embodiment, RXis C1-alkyl, or phenyl, wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen; n is 2; m is 1. In a particularly preferred embodiment, the compound of formula (I) is selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- Attorney Docket No.063692-504001WO azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide , and 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- azaspiro[3.3]heptane-6-carboxamide. In another particularly preferred embodiment, the compound of formula (I) is a Attorney Docket No.063692-504001WO compound selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4- yl)methyl)-N-(2-(diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2- azaspiro[3.3]heptane-6-carboxamide, Attorney Docket No.063692-504001WO 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-cyanophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[5-methyl-2-(p-tolyl)-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl(1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3-hydroxy- 3-azetidinyl)acetamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(2,2,2-trifluoroethylamino)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, Attorney Docket No.063692-504001WO N-[2-(3,3-difluoro-1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, (2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6-spiro[3.3]heptyl)[(S)-3- methyl-1-piperazinyl]methanone, {2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-2-aza-6-spiro[3.3]heptyl}[(S)-3-methyl-1- piperazinyl]methanone, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-2-(ethylamino)ethyl-2-{[4-(p-chlorophenyl)-5-methyl-1,3-oxazol-2-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3- azetidinecarboxamide, and N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl}-3- azetidinecarboxamide. In a further aspect, the present invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I) as defined herein and optionally a pharmaceutically acceptable carrier, diluent or excipient. In yet another aspect, the present invention relates to a compound of formula (I) as defined herein, or a pharmaceutical composition comprising the same as defined herein for use in medicine. In particular, the present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition comprising the same as defined herein for inducing and / or stimulating autophagy. In yet another aspect, the present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition comprising the same as defined herein for use in in the treatment of an autophagy-related disease or condition. In one embodiment, the compound of the present invention as defined herein or the pharmaceutical composition comprising the same as defined herein is for use in the treatment of an autophagy-related disease or condition selected from the group consisting of neurodegenerative diseases, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, systemic lupus erythematosus, epilepsy, cancer, liver diseases (e.g. nonalcoholic fatty liver Attorney Docket No.063692-504001WO disease (NAFLD)), a1 antitrypsin deficiency, Charcot Marie Tooth syndrome, Rett Syndrome, Sickle Cell disease, Wilson Disease, amyloidosis, Gaucher’s diseases, lysosomal and glycogen storage disorders (e.g., Glycogen Storage Disease type 1A (GSD1A)), cystic fibrosis; viral infection and diseases human cytomegalovirus (HCMV) infection, hepatitis B, human immunodeficiency virus infection, Zika virus infection, coronavirus infection, HCoV-229E, HCoV-NL63, betacoronavirus infection, such as HCoV-OC43, SARS-CoV-1, HCoV-HKU1, MERS-CoV or SARS-CoV-2, bacterial infections, metabolic disorders, diabetes, fibrosis, silicosis, diabetic retinopathy, glaucoma, cataracts, age-related macular degeneration, glomerulonephritis, glomerulosclerosis, wound healing disorders, Niemann-Pick type C (NPC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), muscular dystrophy, Duchenne muscular dystrophy, Limb-girdle muscular dystrophy, myopathy, myofibrillar myopathy, hereditary myopathy, diabetic cardiomyopathy, anti-inflammatory disorders, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, irritable bowel syndrome, Crohn’s disease, vascular disorders, stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, Behcet’s syndrome, giant cell arteritis, polymyalgia rheumatic, Wegener’s granulomatosis, Churg-Strauss syndrome, vasculitis, Henoch-Schonlein pruprua, Kawasaki disease, viral infection or replication, pox virus infection, herpes virus infection, asthma, allergic rhinitis, COPD, osteoporosis, organ transplant rejection, psoriasis, hypertrophic scarring (keloid formation), adhesion formations following general or gynecological surgery, lung fibrosis, liver fibrosis, kidney fibrosis, disorders caused by intracellular parasites, malaria, tuberculosis, neuropathic pain, post-operative phantom limb pain or postherpetic neuralgia, allergies, amyotrophic lateral sclerosis (ALS), antigen induced recall response, immune response suppression, muscle degeneration and atrophy, frailty in aging, spinal cord injury, and diseases and conditions involving misfolded and / or nonfolded proteins. In another embodiment of the present invention, said treatment comprises comprises a combination of at least one compound as defined herein with at least one addition pharmaceutically active substance for said autophagy-related disease or condition. In another aspect, the present invention relates to the use of a compound of formula (I) as defined herein for stimulating autophagy in an in-vitro assay. DETAILED DESCRIPTION OF THE INVENTION In the following, preferred embodiments of the substituents in the above compounds of formula (I) are described in further detail. It is to be understood that each preferred embodiment is relevant on its own as well as in combination with other preferred embodiments. Furthermore, Attorney Docket No.063692-504001WO it is to be understood that the preferences in each case also apply to the salts, stereoisomers, tautomers and N-oxides of the compounds of formula (I) of the invention. The invention also includes pharmaceutically acceptable salts, solvates, stereoisomers, tautomers and N-oxides of the compound of formula (I). As indicated above, in a first aspect the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting of L is selected from the group consisting of X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one Attorney Docket No.063692-504001WO or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3. Further, the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned Attorney Docket No.063692-504001WO groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting of L X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, C1-C4-haloalkyl and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis halogen, C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon Attorney Docket No.063692-504001WO and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4- alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3. In one embodiment of the present invention, the following substituent definitions with regard to the substituent A and m are preferred for the compound of formula (I). The substituent definitions for A also apply in combination with the definitions as outlined further below with regard to B, L, X, R1, R2, R3, RN, n and m. Thus, in one embodiment, the present invention relates to a compound according to formula (I) wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; wherein RXis C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O. In another embodiment, the present invention relates to a compound according to formula (I) Attorney Docket No.063692-504001WO wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; wherein RXis halogen, C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O. In a preferred embodiment of the present invention, A is a 5-membered fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9-membered fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; Attorney Docket No.063692-504001WO wherein RXis as defined above. Thus, in a more preferred embodiment of the present invention, A is a substituent selected from the group consisting of With regard to the substituents A1 – A5 it is to be understood that RXand O is as defined above and further below. In a preferred embodiment with regard to the substituents A1, A2, A3, A4 and A5 RXis C1-alkyl, or phenyl, wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen; and O is 1 or 2, perferably O is 2. Thus, in an even more preferred embodiment of the present invention, A is a substituent selected from the group consisting of With regard to the above substituents for A it is to be understood that RXis preferably defined as follows: RXis C1-alkyl, or phenyl, wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from Cl. Therefore, in a particularly preferred embodiment of the present invention, A is a substituent selected from the group consisting of Attorney Docket No.063692-504001WO In an even more particularly preferred embodiment of the present invention, A is a substituent selected from the group consisting of In connection with the above embodiments, it is to be understood that B, L, X, R1, R2, R3, RN, n and m have the meanings as defined above or further below. Furthermore, in connection with the above definitions for A, preferably in connection with the above-definitions for A1, A2, A3, A4 and A5, more preferably in connection with the above definitions for A1*, A2*, A3, A4 and A5, and even more preferably in connection with the above definitions for A1*-I, A1*-II, A2*-I, A3-I, A4-I and A5-I it is to be understood that the curled line in the structural formula indicates the connection to the remainder of the molecule. Further, in a more preferred embodiment of the present invention, m is 1, 2, or 3, preferably m is 1, or 2; more preferably m is 1. In another embodiment of the present invention, the following substituent definitions with regard to the substituent B are preferred for the compound of formula (I). The substituent definitions for B also apply in combination with the definitions as outlined further below or above with regard to A, L, X, R2, R3, RN, RX, n and m. Thus, in one embodiment, the present invention relates to a compound according to formula (I) wherein B is selected from the group consisting of Attorney Docket No.063692-504001WO wherein R1is H, CN, OH, halogen, or C1-C4-alkyl. In a preferred embodiment with regard to the substituent B it is to be understood that R1is preferably defined as follows: R1is H, F, CN or C1-C2-alkyl; preferably R1H, F, or CN. Thus, in an even more preferred embodiment of the present invention the substituent B-3 is selected from the group consisting of In a particularly preferred embodiment of the present invention, B is selected from the group consisting of In an even more particularly preferred embodiment of the present invention B is selected from the group consisting of In an even further particularly preferred embodiment of the present invention B In connection with the above embodiments, it is to be understood that A, L, X, R2, R3, RN, RX, n and m have the meanings as defined above or further below. Furthermore, in connection with the above definitions for the substituent B, preferably in connection with the above definitions for B-1, B-2 and B-3, more preferably in connection with the above definitions for B-3-I, B-3-II and B-3-III, being the moiety connecting A and L, it is to be understood that the curled lines in the structural formulae indicate the two connections to the remainder of the molecule. In another embodiment of the present invention, the following substituent definitions with regard to the substituent L are preferred for the compound of formula (I). The substituent definitions for L also apply in combination with the definitions as outlined further below with regard to that A, B, R1, RXand m. Thus, in one embodiment, the present invention relates to a Attorney Docket No.063692-504001WO compound of formula (I) wherein L is selected from the group consisting of wherein X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R2, R3are independently of each other selected from H, and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O; n is 1, 2 or 3. In another embodiment, the present invention relates to a compound of formula (I) wherein Attorney Docket No.063692-504001WO L is selected from the group consisting of wherein X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R2, R3are independently of each other selected from H, C1-C4-haloalkyl, and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis halogen, C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4- alkyl, or two substituents form =O; n is 1, 2 or 3. In one embodiment of the present invention, the following definitions for RN, R2and R3are preferred: RNis H; R2, R3are independently of each other selected from H, and C1-C2-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the Attorney Docket No.063692-504001WO aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX. In another more preferred embodiment of the present invention, with regard to the substituents L-1, L-2, L-3 and L-4 the following definitions for X, R2, R3, RN, RXand n are preferred: X is a 4- or 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; wherein RXis CH3, CH2CH3; R2, R3are independently of each other selected from H, and C2-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized; RNis H, or C1-alkyl; n is 2 or 3. In an even more preferred embodiment of the present invention, with regard to the substituents L-1, L-2, L-3 and L-4 the following definitions for X, R2, R3, RN, RXand n are preferred: X is selected from the group consisting of R2, R3are independently of each other selected from H, and C2-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized; RNis H, or C1-alkyl; and n is 2 or 3, preferably n is 2. Thus, in a particularly preferred embodiment of the present invention, Attorney Docket No.063692-504001WO L is selected from the group consisting of In one preferred embodiment of the present invention, L is selected from the group consisting of In connection with the above preferred embodiment, it is to be understood that R2, R3, RN, X and n are as defined above or further below. In another preferred embodiment of the present invention, L is selected from the group consisting of In connection with the above preferred embodiment, it is to be understood that R2, R3, RNand n are as defined above. Accordingly, in a more preferred embodiment of the present invention, L is selected from the group consisting of Attorney Docket No.063692-504001WO In an even more preferred embodiment of the present invention, L is selected from the group consisting of In a particularly preferred embodiment of the present invention, Accordingly, in a further particularly preferred embodiment of the present invention, L is selected from the group consisting of In connection with the above embodiments, it is to be understood that A, B, R1, RXand m have the meanings as defined above or further below. Further, in connection with the above definitions for L, preferably in connection with the above definitions for L-1, L-2, L-3 and L-4, more preferably in connection with the above definitions for L-1-I, L-1-II, L-1-III, L-1-IV, L-1- V, L-1-VI, L-2-I, L-3-I, L-3-II and L-4-I it is to be understood that the curled line in the structural formulae indicates the connection to the remainder of the molecule. Thus, in a more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein Attorney Docket No.063692-504001WO In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) m is 1; Attorney Docket No.063692-504001WO B is In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) Attorney Docket No.063692-504001WO In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein Attorney Docket No.063692-504001WO wherein said compound of formula (I) is present in the form of the dihydrochloride salt. In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein A m Attorney Docket No.063692-504001WO B L In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein L In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein A m B Attorney Docket No.063692-504001WO L In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) Attorney Docket No.063692-504001WO In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein Attorney Docket No.063692-504001WO In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) m is 1; Attorney Docket No.063692-504001WO B is B-2; and L In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein said compound of formula (I) is present in the form of the dihydrochloride salt. In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) wherein said compound of formula (I) is present in the form of the dihydrochloride salt. Attorney Docket No.063692-504001WO In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In another more preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (I) In connection with the above definitions for A, B and L it is to be understood that the curled line in the structural formulae indicates the connection to the remainder of the molecule. Furthermore, in connection with the above preferred embodiments it is to be understood that all possible stereoisomers are covered. In addition, in connection with the above preferred embodiments it is to be understood that if chemically feasible the compounds may be present in the form of the free base, the hydrochloride salt or the dihydrochloride salt. Attorney Docket No.063692-504001WO In particularly preferred embodiments, the compound of formula (I) is a compound selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2- Attorney Docket No.063692-504001WO azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, and 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- azaspiro[3.3]heptane-6-carboxamide. In other particularly preferred embodiments, the compound of formula (I) is a compound selected from the group consisting of N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-cyanophenyl)-5- methyl-1,3-oxazol-4-yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[5-methyl-2-(p-tolyl)-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl(1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3-hydroxy- 3-azetidinyl)acetamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, Attorney Docket No.063692-504001WO N-[2-(2,2,2-trifluoroethylamino)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-[2-(3,3-difluoro-1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, (2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6-spiro[3.3]heptyl)[(S)-3- methyl-1-piperazinyl]methanone, {2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-2-aza-6-spiro[3.3]heptyl}[(S)-3-methyl-1- piperazinyl]methanone, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-2-(ethylamino)ethyl-2-{[4-(p-chlorophenyl)-5-methyl-1,3-oxazol-2-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3- azetidinecarboxamide, and N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl}-3- azetidinecarboxamide. In further particularly preferred embodiments, the compound of formula (I) is a compound selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4- yl)methyl)-N-(2-(diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- Attorney Docket No.063692-504001WO azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- Attorney Docket No.063692-504001WO azaspiro[3.3]heptane-6-carboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-cyanophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[5-methyl-2-(p-tolyl)-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl(1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3-hydroxy- 3-azetidinyl)acetamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(2,2,2-trifluoroethylamino)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-[2-(3,3-difluoro-1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, (2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6-spiro[3.3]heptyl)[(S)-3- methyl-1-piperazinyl]methanone, {2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-2-aza-6-spiro[3.3]heptyl}[(S)-3-methyl-1- piperazinyl]methanone, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-2-(ethylamino)ethyl-2-{[4-(p-chlorophenyl)-5-methyl-1,3-oxazol-2-yl]methyl}-2-aza-6- Attorney Docket No.063692-504001WO spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3- azetidinecarboxamide, and N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl}-3- azetidinecarboxamide. Also provided herein is a compound as shown in Table 1. In one embodiment of the present invention, the compound of formula (I) is not a compound selected from the group consisting of Attorney Docket No.063692-504001WO In a further aspect, the present invention relates to a compound according to formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting of L is selected from the group consisting of X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or Attorney Docket No.063692-504001WO substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, C1-C4-haloalkyl and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis halogen, C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4- alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3. In connection with the above aspect, it is to be understood that the embodiments, preferred and particularly preferred embodiments as defined above under the other aspects for the compound of formula (I), as well as for the medical uses and pharmaceutical compositions also apply to this aspect. In a particularly preferred embodiment of this aspect, the compound of formula (I) is selected from the group consisting of Attorney Docket No.063692-504001WO In a particularly preferred embodiment of this aspect, the compound of formula (I) has the following structure . In one embodiment of this aspect, the compound as shown above has the following chemical name: N-2-(ethylamino)ethyl-6-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2,6-diaza-2-spiro[3.3]heptanecarboxamide. In another particularly preferred embodiment of this aspect, the compound of formula (I) has the following structure . In one embodiment of this aspect, the compound as shown above has the following chemical name: N-2-(diethylamino)ethyl-1-[(2-methyl-1,3a-diaza-3-indenyl)methyl]-4- piperidinecarboxamide. In a further particularly preferred embodiment, compound N-2-(diethylamino)ethyl-1-[(2- methyl-1,3a-diaza-3-indenyl)methyl]-4-piperidinecarboxamide is for use in the treatment of Charcot Marie Tooth syndrome. Definitions The term “compound(s) of the present invention" is to be understood as equivalent to the term "compound(s) according to the invention", and also covers a salt, stereoisomer, tautomer or Attorney Docket No.063692-504001WO N-oxide thereof. Pharmaceutically acceptable salts, solvates, stereoisomers, tautomers or N- oxides are also covered. The compounds according to the invention may be amorphous or may exist in one or more different crystalline states (polymorphs), which may have different macroscopic properties such as stability or show different biological properties such as activities. The present invention relates to amorphous and crystalline forms of the compounds of formula (I), mixtures of different crystalline states of the compounds of formula (I), as well as amorphous or crystalline salts thereof. Salts of the compounds according to the invention are preferably pharmaceutically acceptable salts, such as those containing counterions present in drug products listed in the US FDA Orange Book database. They can be formed in a customary manner, e.g., by reacting the compound with an acid of the anion in question, if the compounds according to the invention have a basic functionality, or by reacting acidic compounds according to the invention with a suitable base. This may include addition salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or of organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p- toluenesulphonate, palmoate and stearate. Exemplary salts also include oxalate, chloride, bromide, iodide, bisulphate, acid phosphate, isonicotinate, salicylate, acid citrate, oleate, tannate, pantothenate, bitartrate, ascorbate, gentisinate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, ethanesulfonate, and benzenesulfonate salts. Preferred salts include hydrochloride salts and dihydrochloride salts. The compounds of the present invention can also be present in the form of the free base. The term “free base”, as used herein, refers to the neutral form of the compounds of the present invention, i.e. the compounds not in the form of a salt. The free base of the compounds of the present invention can be formed by common methods known to the person skilled in the art. For example, if the synthesis of the compounds of the invention provides the product compounds in the form of a salt, in particular a salt of an inorganic or organic acid (such as the hydrochloride salt or the dihydrochloride salt), the free base can be obtained, e.g., by treating the salt of an inorganic or organic acid with an alkaline aqueous solution and extracting said solution with an organic solvent. The organic solvent phase containing the free base can then be separated followed by evaporation of the organic solvent and further purification if necessary. Depending on the substitution pattern, the compounds according to the invention may have one or more centres of chirality, including axial chirality. The invention provides both, pure enantiomers or pure diastereomers of the compounds according to the invention, and their mixtures, including racemic mixtures. Suitable compounds according to the invention also Attorney Docket No.063692-504001WO include all possible geometrical stereoisomers (cis / trans isomers or E / Z isomers) and mixtures thereof. E / Z- isomers may be present with respect to, e.g., an alkene, carbon-nitrogen double- bond or amide group. Tautomers may be formed, if a substituent is present at the compound of formula (I) of the present invention, which allows for the formation of tautomers such as keto-enol tautomers, imine-enamine tautomers, amide-imidic acid tautomers or the like. The term "N-oxide" includes any compound of the present invention, which has at least one tertiary nitrogen atom that is oxidized to a N-oxide moiety. The term "substituted", as used herein, means that a hydrogen atom bonded to a designated atom is replaced with a specified substituent, provided that the substitution results in a stable or chemically feasible compound. Unless otherwise indicated, a substituted atom may have one or more substituents and each substituent is independently selected. The term "substitutable", when used in reference to a designated atom, means that attached to the atom is a hydrogen, which can be replaced with a suitable substituent. The definition, wherein each substitutable carbon and heteroatom is independently unsubstituted or substituted means that one or more carbon atoms can be substituted, one or more heteroatoms can be substituted or one or more carbon and one or more heteroatoms can be substituted. When it is referred to certain atoms or moieties being substituted with “one or more” substituents, the term “one or more” is intended to cover at least one substituent, e.g. 1, 2, 3, 4, or 5 substituents, preferably 1, 2, or 3 substituents, more preferably 1, or 2 substituents. When neither the term “unsubstituted” nor “substituted” is explicitly mentioned concerning a moiety, said moiety is to be considered as unsubstituted. The organic moieties mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The prefix Cn-Cm indicates in each case the possible number of carbon atoms in the group. The term "alkyl" as used herein denotes in each case a straight-chain or branched alkyl group having usually from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably 1 to 3 or 1 or 2 carbon atoms. Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2- dimethylpropyl, and 1-ethylpropyl. The term “haloalkyl” as used herein denotes in each case a straight-chain or branched alkyl group having usually from 1 to 4 carbon atoms, preferably 1 to 3 or 1 or 2 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms. Preferred haloalkyl moieties are selected from C1-C4-haloalkyl, more preferably from C1-C3- Attorney Docket No.063692-504001WO haloalkyl or C1-C2-haloalkyl, in particular from C1-C2-fluoroalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2- trifluoroethyl, pentafluoroethyl, and the like. The term “halogen” denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine, chlorine, or bromine, preferably fluorine or chlorine. The term “heterocyclic” or “heterocyclyl” includes, unless otherwise indicated, in general a 3- to 9-membered, preferably a 3- to 6-membered, more preferably 5- or 6-membered monocyclic ring. The heterocycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled, whereas aromatic means that the Hückel (4n + 2) rule is fulfilled. The heterocycle typically comprises one or more, e.g. 1, 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. The remaining ring members are carbon atoms. The saturated or partially or fully unsaturated heterocycles usually comprise 1, 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. The skilled person is aware that S, SO or SO2is to be understood as follows: S . Further, a skilled person is aware that resonance structures of the oxidized forms may be possible. Saturated heterocycles include, unless otherwise indicated, in general 3- to 9- membered, preferably 3- to 6-membered, more preferably 5- or 6-membered monocyclic rings comprising 3 to 9, preferably 3 to 6, more preferably 5 or 6 atoms comprising at least one heteroatom. The term “heterobicyclic” or heterobicyclyl” includes, unless otherwise indicated, in general 6 to 14 membered, preferably 7- to 12-membered or 8- to 10-membered, more preferably 9- or 10-membered bicyclic rings. The heterbicycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled, whereas aromatic means that the Hückel (4n+2) rule is fulfilled, In principle, for being aromatic it is sufficient if one of the two rings of the bicyclic moieties is aromatic, while the other is non-aromatic. However, it is preferred in connection with the term aromatic that both rings of the bicyclic moiety are aromatic, so that e.g., 8π electrons are present in case of a 9- or 10-membered aromatic Attorney Docket No.063692-504001WO heterobicyclic ring. The heterobicycle typically comprises one or more, e.g. 1, 2, 3, or 4, preferably 1, 2, or 3, more preferably 1, or 2 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO, or SO2. The remaining ring members are carbon atoms. As used in the specification and the claims, the singular forms of “a” and “an” also include the corresponding plurals unless the context clearly dictates otherwise. The same applies for plural forms used herein, which also include the singular forms unless the context clearly dictates otherwise. The terms “about” and “approximately” in the context of the present invention denotes an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation from the indicated numerical value of ±10% and preferably ±5%. It needs to be understood that the term “comprising” is not limiting. For the purposes of the present invention, the term “consisting of” is considered to be a preferred embodiment of the term “comprising of”. If hereinafter a group is defined to comprise at least a certain number of embodiments, this is also meant to encompass a group, which preferably consists of these embodiments only. The term “treatment” is to be understood as also including the option of “prophylaxis”. Thus, whenever reference is made herein to a “treatment” or “treating”, this is to be understood as “treatment and / or prophylaxis” or “treating and / or preventing”. The term “pharmaceutically acceptable excipient, carrier or diluent” refers to a solid or liquid filler, diluent or encapsulating substance, which does not interfere with the effectiveness or the biological activity of the active ingredients and which is not toxic to the host, which may be either humans or animals, to which it is administered. Depending upon the particular route of administration, a variety of pharmaceutically-acceptable carriers such as those well known in the art may be used. Non-limiting examples include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water. Pharmaceutically acceptable carriers or excipients also include diluents (fillers, bulking agents, e.g. lactose, microcrystalline cellulose), disintegrants (e.g. sodium starch glycolate, croscarmellose sodium), binders (e.g. PVP, HPMC), lubricants (e.g. magnesium stearate), glidants (e.g. colloidal SiO2), solvents / co-solvents (e.g. aqueous vehicle, propylene glycol, glycerol), buffering agents (e.g. citrate, gluconates, lactates), preservatives (e.g. Na benzoate, parabens (Me, Pr and Bu), BKC), anti-oxidants (e.g. BHT, BHA, ascorbic acid), wetting agents (e.g. polysorbates, sorbitan esters), Attorney Docket No.063692-504001WO thickening agents (e.g. methylcellulose or hydroxyethylcellulose), sweetening agents (e.g. sorbitol, saccharin, aspartame, acesulfame), flavouring agents (e.g. peppermint, lemon oils, butterscotch, etc.), humectants (e.g. propylene glycol, glycerol, sorbitol). The term “mammal” as used herein includes a mouse, rat, monkey, cat, dog, rabbit, goat, sheep, horse, camel, lama, cow and a human. The terms "subject" and "patient" are used interchangeably and refer to a mammal or a human. The term "therapeutically effective amount" or “pharmaceutically effective amount” refers to a predetermined amount of the compound or pharmaceutical composition which confers a therapeutic effect on the treated subject, at a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect or physician observes a change). Description of pharmaceutical compositions, medical uses and uses according to the present invention The present invention also provides a pharmaceutical composition comprising the compound according to formula (I) and optionally a pharmaceutically acceptable excipient or carrier. The pharmaceutical composition may be formulated for any suitable route of administration including oral, subcutaneous, intravenous, intravenous or epidural patient controlled analgesia (PCA and PCEA), intramuscular, intrathecal, epidural, intracistemal, intraperitoneal, transdermal, topical, buccal, sublingual, transmucosal, inhalation, intra-articular, intranasal, rectal or ocular administration. The pharmaceutical composition may be formulated as a sustained release or controlled release formulation. The present invention also provides the compound according to formula (I) for use in medicine. In one embodiment, the compound according to formula (I) is for use in the treatment of an autophagy-related disease or condition. In one embodiment, the compound according to formula (I) is for use in the treatment of cancer, age-related diseases, and infections. Thus, in one embodiment, the present invention relates to a compound according to formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, Attorney Docket No.063692-504001WO wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting of L is selected from the group consisting of X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said Attorney Docket No.063692-504001WO N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3 for use in the treatment of an autophagy-related disease or condition. In another embodiment, the present invention relates to a compound according to formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; Attorney Docket No.063692-504001WO B is selected from the group consisting of L is selected from the group consisting of X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3 for use in the treatment of cancer, age-related diseases, and infections. In a preferred embodiment, the compound according to formula (I) as defined above is for use in the treatment of cancer, age-related diseases, and infections. In connection with the above embodiments regarding the compounds according to Attorney Docket No.063692-504001WO formula (I) for use in the treatment of an autophagy-related disease or condition as defined above, for use in the treatment of cancer, age-related diseases and infections and for the diseases as selected further below, it is to be understood that the preferred embodiments regarding the substituents A, B, L, X, R1, R2, R3, as well as RN, RX, n and m of the compounds of formula (I) as defined in detail above are also preferred embodiments in this connection. In one embodiment, the compound according to formula (I) is for use in the treatment of a disease or condition selected from the group consisting of neurodegenerative diseases, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, systemic lupus erythematosus, epilepsy, cancer, liver diseases (e.g. nonalcoholic fatty liver disease (NAFLD)), a1 antitrypsin deficiency, Charcot Marie Tooth syndrome, Rett Syndrome, Sickle Cell disease, Wilson Disease, amyloidosis, Gaucher’s diseases, lysosomal and glycogen storage disorders (e.g., Glycogen Storage Disease type 1A (GSD1A)), cystic fibrosis; viral infection and diseases human cytomegalovirus (HCMV) infection, hepatitis B, human immunodeficiency virus infection, Zika virus infection, coronavirus infection, HCoV-229E, HCoV-NL63, betacoronavirus infection, such as HCoV-OC43, SARS-CoV-1, HCoV-HKU1, MERS-CoV or SARS-CoV-2, bacterial infections, metabolic disorders, diabetes, fibrosis, silicosis, diabetic retinopathy, glaucoma, cataracts, age-related macular degeneration, glomerulonephritis, glomerulosclerosis, wound healing disorders, Niemann-Pick type C (NPC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), muscular dystrophy, Duchenne muscular dystrophy, Limb-girdle muscular dystrophy, myopathy, myofibrillar myopathy, hereditary myopathy, diabetic cardiomyopathy, anti-inflammatory disorders, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, irritable bowel syndrome, Crohn’s disease, vascular disorders, stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, Behcet’s syndrome, giant cell arteritis, polymyalgia rheumatic, Wegener’s granulomatosis, Churg-Strauss syndrome, vasculitis, Henoch-Schonlein pruprua, Kawasaki disease, viral infection or replication, pox virus infection, herpes virus infection, asthma, allergic rhinitis, COPD, osteoporosis, organ transplant rejection, psoriasis, hypertrophic scarring (keloid formation), adhesion formations following general or gynecological surgery, lung fibrosis, liver fibrosis, kidney fibrosis, disorders caused by intracellular parasites, malaria, tuberculosis, neuropathic pain, post-operative phantom limb pain or postherpetic neuralgia, allergies, amyotrophic lateral sclerosis (ALS), antigen induced recall response, immune response suppression, muscle degeneration and atrophy, frailty in aging, spinal cord injury, and diseases and conditions involving misfolded and / or nonfolded proteins. In a preferred embodiment, the compound according to formula (I) is for use in the Attorney Docket No.063692-504001WO treatment of Charcot Marie Tooth syndrome. In one embodiment, the compound of formula (I) is selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-5-oxa-2- azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, Attorney Docket No.063692-504001WO 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, and 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- azaspiro[3.3]heptane-6-carboxamide. In another embodiment, the compound of formula (I) is a compound selected from the group consisting of N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-cyanophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[5-methyl-2-(p-tolyl)-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl(1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3-hydroxy- 3-azetidinyl)acetamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- Attorney Docket No.063692-504001WO spiro[3.3]heptanecarboxamide, N-[2-(2,2,2-trifluoroethylamino)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-[2-(3,3-difluoro-1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, (2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6-spiro[3.3]heptyl)[(S)-3- methyl-1-piperazinyl]methanone, {2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-2-aza-6-spiro[3.3]heptyl}[(S)-3-methyl-1- piperazinyl]methanone, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-2-(ethylamino)ethyl-2-{[4-(p-chlorophenyl)-5-methyl-1,3-oxazol-2-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3- azetidinecarboxamide, and N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl}-3- azetidinecarboxamide. In a further embodiment, the compound of formula (I) is a compound selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, Attorney Docket No.063692-504001WO 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, Attorney Docket No.063692-504001WO 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-cyanophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[5-methyl-2-(p-tolyl)-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(diethylamino)ethyl(1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3-hydroxy- 3-azetidinyl)acetamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-[2-(2,2,2-trifluoroethylamino)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-[2-(3,3-difluoro-1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, (2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6-spiro[3.3]heptyl)[(S)-3- methyl-1-piperazinyl]methanone, {2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-2-aza-6-spiro[3.3]heptyl}[(S)-3-methyl-1- piperazinyl]methanone, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide, Attorney Docket No.063692-504001WO N-2-(ethylamino)ethyl-2-{[4-(p-chlorophenyl)-5-methyl-1,3-oxazol-2-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide, N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3- azetidinecarboxamide, and N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl}-3- azetidinecarboxamide. The compound according to formula (I) may be administered via any suitable route of administration including oral, subcutaneous, intravenous, intravenous or epidural patient controlled analgesia (PCA and PCEA), intramuscular, intrathecal, epidural, intracistemal, intraperitoneal, transdermal, topical, buccal, sublingual, transmucosal, inhalation, intra-articular, intranasal, rectal or ocular administration. The compound according to formula (I) may be administered in any suitable dosing scheme ranging from hourly, daily, weekly, monthly to yearly administration. The dosing scheme may also include cyclic dosing schemes involving time periods without administration after which administration is resumed. The dosing scheme may be adapted for the route of administration applied. The compound according to formula (I) may be administered in a fixed amount or may be administered in an amount that is adapted to the patient’s weight. The compound according to formula (I) may also be administered in combination with one or more further therapeutic agents. The compound according to formula (I) and the one or more further therapeutic agents may be provided in a combined formulation or in separate formulations. Administration may occur in parallel (at the same time point) or sequentially (at different time points). In one embodiment, compound according to formula (I) and the one or more further therapeutic agents are each administered according to their established dosing regimens. The present invention also provides a method of treating a patient, wherein the method comprises administering a therapeutically effective amount of the compound according to formula (I) to a patient in need thereof. In one embodiment, the patient suffers from any of the diseases or conditions listed herein. The present invention also provides a use of the compound according to formula (I) in a cosmetic method. The method may comprise the step of applying the compound according to formula (I) to the skin of a mammal. In one embodiment, the use is for reducing cutaneous aging. It is yet a further object of the present invention to provide a use of the compound according to formula (I) for stimulating autophagy in an in-vitro assay. The assay may be a cell- Attorney Docket No.063692-504001WO based assay involving a fluorescent dye. Stimulation of autophagy may be analyzed by measuring increased acidic vesicle formation. In one embodiment, acidic vesical formation is increased by the compound according to formula (I) by at least 25%, by at least 50% or by at least 100% in comparison to untreated control cells. In one embodiment, the cell-based assay is a mammalian-cell based assay. The present invention is further illustrated by the following examples. Examples Materials and Methods, Synthetic procedures The compounds of the present invention were prepared according to the following synthetic procedures and Examples and are further exemplified by the following specific examples. Unless otherwise indicated in the following, the starting materials are obtained from commercial suppliers, which is indicated for example by the CAS numbers, and used without further purification. However, it is to be understood that in case the CAS number is not indicated below a starting material, this does not mean that the starting material was not obtained from commercial suppliers. Further, it is to be understood that the starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials. Liquid chromatography mass spectrometry (LCMS) LCMS spectra were recorded on a Waters 996 Photodiode Array Detector equipped with Waters Micromass ZQ detector. Standard set-up: Column ID WELCH C184.6 x 150mm, 5 µm Machine Details Column temperature: 35°C, Auto sampler temperature: 15°C, Mobile Phase A: 5mM Ammonium Acetate and 0.1 % Formic acid (pH =3.50) in Milli Q water, Mobile Phase B: Methanol Mobile phase gradient details T = 0 min (90% A, 10% B); T = 7.0 min (10% A, 90% B); gradient to T = 9.0 min (0% A, 100% B); gradient to T = 14.00 min (0% A, 100% B); T = 14.01 min (90% A, 10% B); end of run at T = 17 min (90% A, 10% B), Flow rate:- 1.0 mL / min, Run Time:- 17 min, UV Detection Method:- PDA. Mass parameter Probe: ESI, Mode of Ionisation: Positive and Negative, Cone voltage:-30 and 10 V, capillary voltage:- 3.0 KV, Extractor Voltage:-2 V, Rf Lens:- 0.1 V, Temperature of source:-120°C,Temperature of Probe:- 400 °C,Cone Gas Flow:- 100 L / Hr, Desolvation Gas Attorney Docket No.063692-504001WO flow:-800 L / Hr. For all other compounds, LCMS spectra were recorded on a Waters Acquity Ultra performance LC system equipped with a Photodiode Array (PDA) detector with an attached Quadrupole Dalton (QDa) detector. Standard set-up: Column ID: X-BRIDGE BEH C182.1 x 50mm, 2.5µm Machine details Column temperature: 35°C, Auto sampler temperature: 5°C, Mobile Phase A: 0.1 % Formic acid in Milli Q water (pH= 2.70), Mobile Phase B : 0.1% Formic acid in Milli Q water : Acetonitrile (10:90). Mobile phase gradient details T = 0 min (97% A, 3% B) flow : 0.8 mL / min; T = 0.75 min (97% A, 3% B) flow : 0.8 mL / min; gradient to T = 2.7 min (2% A, 98% B) flow : 0.8 mL / min; gradient to T = 3 min (0% A, 100% B) flow : 1 mL / min; T = 3.5 min (0% A, 100% B) flow : 1 mL / min; gradient to T= 3.51 min (97% A, 3% B) flow : 0.8 mL / min; end of run at T = 4 min (97% A, 3% B), Flow rate: 0.8 mL / min, Run Time:- 4 min, UV Detection Method:- PDA. Mass parameter Probe:-ESI, Mode of Ionisation: Positive and Negative, Cone voltage :-30 V and 10 V, capillary voltage:- 0.8 KV, Extractor Voltage:- 1 V, Rf Lens:- 0.1 V, Temperature of source:-120°C,Temperature of Probe:- 600°C Cone Gas Flow:- Default , Desolvation Gas flow:- Default. High-performance liquid chromatography (HPLC) HPLC was carried out using a Waters Alliance e2695 equipped with a 2998 Photodiode Array (PDA) detector. Set-up used: Column temperature 25°C Auto sampler temperature 25°C Mobile Phase A 0.05% ammonium hydroxide solution in HPLC water Mobile Phase B 100% ACETONITRILE Mobile phase gradient details T = 0 min (10% A, 90% B) flow : 1 mL / min; T = 7 min (90%A, 10% B) flow : 1 mL / min; gradient to T = 9 min (100% A, 0% B) flow : 1 mL / min; gradient to T = 14 min (100% A, 0% B) flow : 1 mL / min; T = 14.01 min (10% A, 90% B) flow : 1 mL / min; gradient to T= 17 min (10% A, 90% B) flow : 1 mL / min; end of run at T = 17 min (10% A, 90% B), Flow rate: 1 mL / min, Run Time:- 17 min, UV Detection Method:- PDA. For all other compounds, HPLC was carried out using a SHIMADZU i-Series LC-2050C 3D system with a Photodiode Array (PDA) detector with one of the following columns: Sunfire Attorney Docket No.063692-504001WO C18 (150 x 4.6mm), 3.5μm; Xtimate C18 (150 x 4.6mm), 5μm; Atlantis C18 (250 x 4.6mm), 5μm; Atlantis C18 (150 x 4.6mm), 5μm. Standard set-up for SHIMADZU i-Series LC-2050C 3D with PDA detector: Column temperature 25°C Auto sampler temperature 25°C Mobile Phase A 0.05% Trifluoroacetic acid in HPLC water Mobile Phase B 100% Acetonitrile Mobile phase gradient details T = 0 min (90% A, 10% B) flow : 1 mL / min; T = 7 min (10%A, 90% B) flow : 1 mL / min; gradient to T = 9 min (0% A, 100% B) flow : 1 mL / min; gradient to T = 14 min (0% A, 100% B) flow : 1 mL / min; T = 14.01 min (90% A, 10% B) flow : 1 mL / min; gradient to T= 17 min (90% A, 10% B) flow : 1 mL / min; end of run at T = 17 min (90% A, 10% B), Flow rate: 1 mL / min, Run Time:- 17 min, UV Detection Method:- PDA. Chiral high-performance liquid chromatography (chiral HPLC) Chiral HPLC was carried out using a Waters SFC Investigator system with 2998 Photodiode Array (PDA) detector or a Shimadzu LC-20 AD system with Diode-Array Detection (DAD) detector with one of the following columns: CHIRALPAK® IA (250 x 4.6 mm), 5 µm; CHIRALPAK® IG (250 x 4.6 mm), 5 µm; CHIRALCEL® OD-H (250 x 4.6 mm), 5 µm; CHIRALPAK® IH (250X4.6 mm), 5 µm; YMC CELLULOSE SC (250 x 4.6 mm), 5 µm; CHIRALPAK® IB-N (250 x 4.6mm), 5 µm; CHIRALPAK® AD-H (250*4.6 mm), 5 µm. Full details on chiral HPLC for a representative selection of compounds are provided further below in the detailed synthetic procedures. Key Starting Materials not readily available Synthesis of 2-(4-chlorophenyl)-5-methyloxazole-4-carbaldehyde KSM 1 Attorney Docket No.063692-504001WO Step-1A: Synthesis of ethyl 2-(4-chlorophenyl)-5-methyloxazole-4-carboxylate: Procedure: To a stirred solution of 4-chlorobenzamide (5.0 g, 32.13mmol) in Xylene (5V, 25mL) was added ethyl 2-chloro-3-oxobutanoate (6.87 g, 41.77mmol) at room temperature. The reaction mixture was stirred at 140°C for 16 hours. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, the reaction mixture was concentrated under vacuum to get crude. which was purified by Glass column chromatography (product was eluted at 4% EtOAc in Hexane) to get pure ethyl 2-(4-chlorophenyl)-5-methyloxazole-4-carboxylate (5.5g, 17.04% yield) as pale yellow solid. LCMS [ESI, M, M+2]: 265.8, 267.7 (RT: 2.046min, Purity: 100.00%) Step-1B: Synthesis of (2-(4-chlorophenyl)-5-methyloxazol-4-yl)methanol: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of ethyl 2-(4-chlorophenyl)-5-methyloxazole-4-carboxylate (5.5 g, 20.70mmol) in THF (10V, 55mL) was added LAH in 1M THF (31.05 mL, 14.11 mmol) at -78 °C. The reaction mixture was stirred at room temperature for 1 hour. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, the reaction mixture was diluted with EtOAc (100 mL) and then Water (800 mL) was added. Resultant mixture was filtered through celite bed, separate the organic layer, which was dried over Sodium Sulphate and concentrated under vacuum to get pure (2-(4-chlorophenyl)-5-methyloxazol-4-yl)methanol (4.5g, 97.20% yield) as white solid. LCMS [ESI, M, M+2]: 224.2, 226.2 (RT: 1.861min, Purity: 91.69%) Step-1C: Synthesis of 2-(4-chlorophenyl)-5-methyloxazole-4-carbaldehyde: Procedure: To a stirred solution of (2-(4-chlorophenyl)-5-methyloxazol-4-yl) methanol (0.3g, 1.34mmol) in DCM (10V, 3mL) was added DMP (2.84g, 6.70mmol) at RT. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC analysis, after completion of reaction, the reaction mixture was poured in sat. solution of NaHCO3(15 mL) and product was extracted by DCM (3 X 30 mL). Organic layer was dried over Sodium Sulphate, concentrated under vacuum to get pure 2-(4-chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.2g, 67.27% yield) as yellow solid. Crude was directly used for the next step. Synthesis of methyl 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylate KSM 2 Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 2-(tert-butyl) 6-methyl 2-azaspiro[3.3]heptane-2,6-dicarboxylate (2.0g, 7.83mmol) in DCM (20mL, 10V) was added TFA (10mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by trituration using diethyl ether: pentane (1:1, 50mL) to get methyl 2-azaspiro[3.3]heptane-6-carboxylate 2,2,2-trifluoroacetate(2.0g, quantitative yield) Attorney Docket No.063692-504001WO as a white sticky solid.1H NMR (400 MHz, MeOD) δ: 4.08 (d, J = 9.2Hz, 4H), 3.69 (s, 3H), 3.08 – 3.02 (m, 1H), 2.61 - 2.54 (m, 2H), 2.52 – 2.44 (m, 2H). Step-2: Synthesis of methyl 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylate: Procedure: To a stirred solution of methyl 2-azaspiro[3.3]heptane-6-carboxylate 2,2,2-trifluoroacetate(0.7g, 4.50mmol) in MeOH (5mL, 10V) was added TEA (1.14g, 2.21mmol) at 0°C. After 5min, 2-(4- chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.5g, 1.8mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 5h. Then NaCNBH3(0.283g, 4.50mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 85°C for 11h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 8% MeOH in DCM) to get methyl 2-((2-(4- chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6-carboxylate (0.75g, 20.67% yield) as yellow solid. LCMS [ESI, M, M+2]: 361.3, 363.2 (RT: 2.154 min, Purity: 84.63%) Note: We have performed 0.5g x 2 batches and yield is combined for this step. Step-3: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptane-6-carboxylic acid: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of methyl 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3] heptane-6-carboxylate (0.75g, 2.07mmol) in MeOH (10V, 7.5mL) was added 2M NaOH (5V, 5.25mL) at rt. The reaction mixture was stirred at for 1 hour. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, Reaction mixture was evaporated under vacuum and then pH was balanced to neutral with 2N HCl, precipitates were collected by filtration to get pure 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3] heptane-6-carboxylic acid (0.55g, 76.30% yield) as yellow solid. LCMS [ESI, M, M+2]: 347.3, 349.3 (RT: 1.630min, Purity: 90.60%) Synthesis of N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate KSM 3 Attorney Docket No.063692-504001WO Step-1A: Synthesis of tert-butyl 6-((2-(diethylamino)ethyl)carbamoyl)-2-azaspiro[3.3] heptane-2-carboxylate: Procedure: To a stirred solution of 2-(tert-butoxycarbonyl)-2-azaspiro[3.3]heptane-6-carboxylic acid (1.0g, 4.10mmol) in DMF (10mL, 10V) was added HATU (2.36g, 6.20mmol) at rt. After 20 min, N1, N1-diethylethane-1,2-diamine (0.57g, 4.90mmol) was added at rt. After 10min, DIPEA (1.6g, 12.30mmol) was added and the resulting reaction mixture was stirred at room temperature for 2h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured in cold water (100mL) and extracted with EtOAc (3 X 90mL). Combine organic layer was dried over Na2SO4, filtered and concentrated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 8% MeOH in DCM) to get tert-butyl 6-((2-(diethylamino)ethyl)carbamoyl)-2- azaspiro[3.3]heptane-2-carboxylate (0.9g, 63.97% yield) as a brown sticky solid. LCMS [ESI, M+1]: 340.2 (RT: 1.591min, Purity: 42.78%) Step-1B: Synthesis of N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2-trifluoroacetate KSM 3 Procedure: To a stirred solution of tert-butyl 6-((2-(diethylamino)ethyl)carbamoyl)-2-azaspiro[3.3]heptane- 2-carboxylate (0.9g, 2.60mmol) in DCM (9mL, 10V) was added TFA (4.5mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under Attorney Docket No.063692-504001WO vacuum to get crude material, which was purified by trituration using diethyl ether (20mL) and pentane (20mL) to get N-(2-(diethylamino) ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2-trifluoroacetate (0.85g, quantitative yield) as a yellow sticky solid.1H NMR (400 MHz, MeOD) δ: 4.09 (d, J=10 Hz, 4H), 3.54 (t, J=6.4 Hz, 2H), 3.33–3.25 (m, 6H), 3.03-2.96 (m, 3H), 2.53–2.50 (m, 2H), 2.47–2.45 (m, 2H), 1.32 (t, J=7.2 Hz, 6H). Synthesis of N-(2-(pyrrolidin-1-yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate KSM 4 Step-1: Synthesis of tert-butyl 6-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)-2- azaspiro[3.3]heptane-2-carboxylate: Procedure: To a stirred solution of 2-(tert-butoxycarbonyl)-2-azaspiro[3.3]heptane-6-carboxylic acid (1.0 g, 4.10mmol) in DMF (10V, 10mL) was added HATU (2.36g, 6.20mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 mins. Then 2-(pyrrolidin-1-yl)ethan- 1-amine (0.615g, 5.30mmol) and after 10 min DIPEA (1.60g, 12.4mmol) was added to reaction mixture. Reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, the reaction mixture was Attorney Docket No.063692-504001WO poured into water (100 mL) and product was extracted by EtOAc (2 x 70mL). Organic layer was dried over Na2SO4 and evaporated under vacuum to get crude material, which was purified by flash column chromatography product was eluted at 8% MeOH in DCM to get tert-butyl 6-((2- (pyrrolidin-1-yl)ethyl)carbamoyl)-2-azaspiro[3.3]heptane-2-carboxylate (1.0g, 71.50% yield) as a brown sticky solid. LCMS [ESI, M+1]: 338.0 (RT: 1.102min, Purity: 77.65%) Step-2: Synthesis of N-(2-(pyrrolidin-1-yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2-trifluoroacetate KSM 4 Procedure: To a stirred solution of tert-butyl 6-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)-2- azaspiro[3.3]heptane-2-carboxylate (1.0g, 2.96mmol) in DCM (10mL, 10V) was added TFA (10mL, 5V) at 0°C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide 2,2,2-trifluoroacetate(1.8g, quantitative yield) as a yellow sticky solid. MASS [ESI, M+1]:238.3 Synthesis of methyl 2-azaspiro[3.3]heptane-6-carboxylate 2,2,2-trifluoroacetate KSM 5 Procedure: To a stirred solution of 2-(tert-butyl) 6-methyl 2-azaspiro[3.3]heptane-2,6-dicarboxylate (2.0g, Attorney Docket No.063692-504001WO 7.83mmol) in DCM (20mL, 10V) was added TFA (10mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by trituration using diethyl ether: pentane (1:1, 30mL) to get methyl 2-azaspiro[3.3]heptane-6-carboxylate 2,2,2-trifluoroacetate (2.0g, quantitative yield) as a white sticky solid.1H NMR (400 MHz, MeOD) δ: 4.08 (d, J= 9.2Hz, 4H), 3.69 (s, 3H), 3.08–3.02 (m, 1H), 2.61- 2.54 (m, 2H), 2.52–2.44 (m, 2H). Synthesis of 3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazole-5-carbaldehyde KSM 6 Step-1: Synthesis of (E)-1-(4-chlorobenzylidene)-2-methylhydrazine: Procedure: To a stirred solution of 4-chlorobenzaldehyde (1.0g, 7.10mmol) in THF (10mL, 10V) was added methyl hydrazine (0.32g, 7.10mmol) at rt. The reaction mixture was stirred at room temperature Attorney Docket No.063692-504001WO for 16h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get (E)-1-(4- chlorobenzylidene)-2-methylhydrazine (1.0g, 83.36% yield) as a yellow solid. Crude material was directly used for the next step. LCMS [ESI, M, M+2]: 168.8, 170.7 (RT: 1.617min, Purity: 84.48%) Step-2: Synthesis of (3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methanol: Procedure: To a stirred solution of (E)-1-(4-chlorobenzylidene)-2-methylhydrazine (1.0g, 5.93mmol) in ACN (10mL, 10V) was added 2-aminoethan-1-ol (1.60, 17.79mmol), tert-Butyl hydroperoxide (1.08g, 17.79mmol) and I2(0.3g,1.10mmol) at 0°C. The reaction mixture was stirred at 70°C for 3h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured in water (100mL) and extracted with EtOAc (3 X 80mL). Combine organic layer was dried over Na2SO4, filtered and concentrated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 100% EtOAc in hexane) to get (3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl) methanol (0.45g, 33.93% yield) as a yellow solid. LCMS [M, M+2]: 223.9, 225.7 (RT: 1.292min, Purity: 91.13%) Step-3: Synthesis of 3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazole-5-carbaldehyde: Procedure: To a stirred solution of (3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methanol (0.45g, 2.01mmol) in DCM (4.5mL, 10V) was added DMP (4.26g, 10.05mmol) at rt. The resulting reaction mixture was stirred at room temperature for 2h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was quenched with sat. Na2CO3 Attorney Docket No.063692-504001WO solution (20mL) and then filtered through celite. Filtrate was extracted with DCM (2 X 20mL), combine organic layer were dried over Na2SO4, filtered and concentrate under vacuum to get 3- (4-chlorophenyl)-1-methyl-1H-1,2,4-triazole-5-carbaldehyde (0.4g, 89.70% yield) as a yellow solid. Crude material was directly used for the next step reaction. Experimental protocol for Compounds 1-1 and 1-2: Step-1: Synthesis of tert-butyl 6-((2-(diethylamino)ethyl)carbamoyl)-5-oxa-2-azaspiro[3.4] octane-2-carboxylate Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 2-(tert-butoxycarbonyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxylic acid (0.3g, 1.16mmol) in DMF (10V, 3mL) was added HATU (0.66g, 1.74mmol) at room temperature. The reaction mixture was stirred at room temperature for 20 min. Then N1, N1- diethylethane-1,2-diamine (0.16g, 1.39mmol) and after 10 min DIPEA (0.45g, 3.49mmol) was added to reaction mixture, the reaction mixture was stirred at room temperature for 1h, progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured into water (80 mL) and product was extracted by EtOAc (3 x 70 mL). Organic layer was dried with Na2SO4 and concentrated under vacuum to get crude material, which was purified by column chromatography (product eluted at 5% MeOH in DCM) to get pure tert-butyl 6-((2-(diethylamino)ethyl)carbamoyl)-5-oxa-2-azaspiro[3.4]octane-2- carboxylate (0.3g, 72.38% yield) as yellow sticky solid.1H NMR (400 MHz, MeOD) δ: 4.45 (t, J= 7.6Hz, 14.8Hz, 1H), 4.19 (d, J= 9.2 Hz,1H), 4.036– 4.013 (m, 1H), 4.00-3.91 (m, 2H), 3.58–3.40 (m, 2H), 3.36 (s, 2H), 3.03-2.98 (m, 4H), 2.39- 2.31(m, 1H), 2.22-2.10 (m, 2H), 2.05-1.95 (m, 1H), 1.46 (s, 9H), 1.23 (t, J= 7.2 Hz, 14.8 Hz, 6H). Step-2: Synthesis of N-(2-(diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide 2,2,2-trifluoroacetate (1:1): Attorney Docket No.063692-504001WO Procedure: To a stirred solution of tert-butyl 6-((2-(diethylamino)ethyl)carbamoyl)-5-oxa-2- azaspiro[3.4]octane-2-carboxylate (0.3g, 0.84mmol) in DCM (3mL, 10V) was added TFA (1.5mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by trituration using diethyl ether: pentane (1:1, 20mL) to get N-(2-(diethylamino)ethyl)-5-oxa-2- azaspiro[3.4]octane-6-carboxamide 2,2,2-trifluoroacetate(0.42g, Quantitative yield) as a yellow sticky liquid.1H NMR (400 MHz, MeOD) δ: 4.47 (t, J= 6.4Hz, 7.6Hz, 1H), 4.30 (d, J= 11.6 Hz,1H), 4.19 (d, J= 11.6 Hz, 1H), 4.25-4.00 (m, 2H), 3.62–3.49 (m, 2H), 3.25-3.10(m, 6H), 2.35-2.10 (m, 3H), 2.00-1.85(m, 1H), 2.22-2.10 (m, 2H), 2.05-1.95 (m, 1H), 1.21-1.17 (m, 6H). Step-3: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino) ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide:

[0002] Attorney Docket No.063692-504001WO Procedure: To a stirred solution of N-(2-(diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide 2,2,2-trifluoroacetate(0.41g, 1.62mmol) in MeOH (2mL, 10V) was added TEA (0.36g, 3.60mmol) at 0°C. After 10min, 2-(4-chlorophenyl)-5-methyloxazole-4-carbaldehyde, KSM1, (0.2g, 0.90mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 5h. Then NaCNBH3 (0.11g, 1.80mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 850C for 11h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was quenched with water (10mL) and concentrated under vacuum to get crude material, which was purified by flash column chromatography [product eluted at 55% of (10% MeOH in DCM with 0.1% of NH4OH) in DCM] to get 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4] octane-6-carboxamide (0.4g, 42.53% yield) as a yellow sticky solid. LCMS [ESI, M, M+2]: 461.4, 463.4 (RT: 5.280 min, Purity: 98.10%) HPLC Purity: (RT: 7.08 min, Purity: 98.18%) Chiral HPLC Purity: RT: 1.969 min, Purity: 49.10% + RT: 2.069 min, Purity: 49.29% Step-4: SFC Separation of racemic 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N- (2-(diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide: Attorney Docket No.063692-504001WO Enantiomer-1: 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide Compound 1-1 Mass: 85 mg LCMS [ESI, M, M+2]: 461.4, 463.4 (RT: 3.347 min, Purity: 100%) HPLC Purity: (RT: 3.562 min, Purity: 100.00%) Chiral HPLC Purity: (RT: 1.972min, Purity: 99.23%) Instrument Name: WATERS ACQUITY UPC2 Chromatographic separation was conducted with Waters ACQUITY UPC2 system with 2998 PDA detector. The column used was CHIRALPAK IG-3100*3mm, 3micron and the compounds were eluted with, Mobile Phase A: Liq.CO2, Mobile Phase B: 0.1% Methanolic ammonia in Methanol: Acetonitrile(50:50) with Gradient method; with Flow rate= 2 ml / min; analysis time 5 min.1H NMR (400 MHz, MeOD): δ 7.98 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 4.36 (t, J=6.4 Hz, J=14 Hz,1H), 3.81 (s, 2H), 3.58 (d, J=8.8 Hz, 1H), 3.50-3.44 (m, 3H), 3.33-3.30 (m, 1H), 2.61– 2.56 (m, 7H), 2.33-2.30 (m, 1H), 2.16-2.12 (m, 3H), 2.14–1.96 (m, 1H), 1.06 (t, J=7.2 Hz, 14.4 Hz, 6H). Enantiomer-2: 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide Compound 1-2 Mass: 80 mg LCMS [ESI, M, M+2]: 461.4, 463.4 (RT: 3.342 min, Purity: 100%) HPLC Purity: (RT: 3.342 min, Purity: 100.00%) Chiral HPLC Purity: (RT: 2.074min, Purity: 97.14%) Instrument Name: WATERS ACQUITY UPC2 Chromatographic separation was conducted with Waters ACQUITY UPC2 system with 2998 PDA detector. The column used was CHIRALPAK IG-3100*3mm, 3micron and the compounds Attorney Docket No.063692-504001WO were eluted with, Mobile Phase A: Liq.CO2, Mobile Phase B: 0.1% Methanolic ammonia in Methanol: Acetonitrile(50:50) with Gradient method; with Flow rate= 2 ml / min; analysis time 5 min.1H NMR (400 MHz, MeOD): δ 7.98 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 4.36 (t, J=6.4 Hz, J=14 Hz,1H), 3.81 (s, 2H), 3.58 (d, J=8.8 Hz, 1H), 3.50-3.44 (m, 3H), 3.33-3.30 (m, 1H), 2.61–2.56 (m, 7H), 2.33-2.30 (m, 1H), 2.16-2.12 (m, 3H), 2.14–1.96 (m, 1H), 1.06 (t, J=7.2 Hz, 14.4 Hz, 6H). Experimental protocol for Compound 2: Step-1: Synthesis of methyl (4-chlorobenzoyl)-L-alaninate Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 4-chlorobenzoic acid (3.0g, 19.10mmol) in DMF (30mL, 10V) was added CDI (4.65g, 28.0mmol) at 00C, stirred the reaction mixture at 00C for 1h, then added methyl L-alaninate (2.94g, 21.0mmol) to reaction mixture at 00C, stirred the reaction mixture further 1h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, reaction mixture was poured into cold water (50 mL) to obtain white precipitates, which was collected by filtration and dried to get pure methyl (4-chlorobenzoyl)- L-alaninate (3.0g, 64.78% yield) as an off white solid. LCMS [ESI, M, M+2]: 242.2, 244.2.2 (RT: 1.849min, Purity: 88.20%) Step-2: Synthesis of (4-chlorobenzoyl)-L-alanine : Procedure: To a stirred solution of methyl (4-chlorobenzoyl)-L-alaninate (3.0g, 12.4mmol) in MeOH (30mL, 10V) was added 2M NaOH (21mL, 7V) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was evaporated under vacuum to remove MeOH, then added 2N HCl was added to crude upto pH~7 to get white precipitates, which was collected by filtration and dried it to get pure (4-chlorobenzoyl)-L- alanine (2.5g, 88.47% yield) as white solid. LCMS [ESI, M, M-2]: 228.3, 226.3 (RT: 1.657min, Purity: 81.87%) Attorney Docket No.063692-504001WO Step-3: Synthesis of methyl 2-(4-chlorophenyl)-4-methyloxazole-5-carboxylate : Procedure: To a stirred solution of (4-chlorobenzoyl)-L-alanine (2.5g, 10.0mmol) in Benzene (18V, 45mL) and DCM (67V, 167.5mL was added oxalyl chloride (13.93g, 109.0mmol) at 00C. The reaction mixture was stirred at room temperature for 16 h, progress of reaction was monitored by TLC, then reaction mixture was evaporated under vacuum to get crude material, in resultant mixture, TEA (2.22g, 21.0mmol) and MeOH (30V, 75mL) were added respectively. The reaction mixture was stirred at room temperature for 3h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was evaporated under vacuum to get crude material, which was purified using flash column chromatography (product eluted at 19% EtOAc in Hexane) to get pure methyl 2-(4-chlorophenyl)-4-methyloxazole-5- carboxylate (0.45g, 16.28% yield) as white solid. LCMS [ESI, M, M+2]: 251.8, 253.7 (RT: 1.896min, Purity: 90.23%) Step-4: Synthesis of (2-(4-chlorophenyl)-4-methyloxazol-5-yl)methanol: Procedure: To a stirred solution of methyl 2-(4-chlorophenyl)-4-methyloxazole-5-carboxylate (0.45g, 1.70mmol) in THF (10V, 4.5mL) was added LAH in 1M THF (2.68 mL, 2.61 mmol) at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, the reaction mixture was diluted with EtOAc (8 mL) and Water (10 mL). Resultant mixture was filtered through celite bed. In the filtrate another water (70mL) was added and product was extracted through EtOAc (3 x 60 mL). Organic layer was dried over Sodium Sulphate and concentrated under vacuum to get Attorney Docket No.063692-504001WO pure (2-(4-chlorophenyl)-5-methyloxazol-4-yl)methanol (0.3g, 75.02% yield) as white solid. LCMS [ESI, M, M+2]: 223.9, 225.7 (RT: 1.408min, Purity: 99.72%) Step-5: Synthesis of 2-(4-chlorophenyl)-5-methyloxazole-4-carbaldehyde: Procedure: To a stirred solution of (2-(4-chlorophenyl)-5-methyloxazol-4-yl) methanol (0.25g, 1.10mmol) in DCM (10V, 2.5mL) was added DMP (2.36g, 5.50mmol) at RT. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC analysis, after completion of reaction, sat. solution of NaHCO3(10 mL) was added to quench the excess DMP then water (50mL) was added and product was extracted by DCM (3 x 40 mL). Organic layer was dried over Sodium Sulphate, concentrated under vacuum to get pure 2-(4-chlorophenyl)-5- methyloxazole-4-carbaldehyde (0.2g, 80.73% yield) as yellow solid. Crude was directly used for the next step. Step-6: Synthesis of 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2- (diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide: Procedure: To a stirred solution of N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate(0.43g, 1.80mmol) in MeOH (2 mL, 10V) was added TEA (0.36g, 3.60mmol) at 0°C. After 10min, 2-(4-chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.2g, 0.90mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 5h. Then NaCNBH3(0.11g, 1.80mmol) was added at 0 °C under N2atmosphere and the resulting reaction Attorney Docket No.063692-504001WO mixture was stirred at 850C for 16h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was quenched with water (10mL) and concentrated under vacuum to get crude material, which was purified by reverse phase column chromatography, product was eluted at 10% ACN in Water to get 2-((2-(4-chlorophenyl)-4- methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6- carboxamide, Compound 2 (0.12g, 29.88% yield) as a white sticky solid. LCMS [ESI, M, M+2]: 445.4, 447.4 (RT: 3.333 min, Purity: 97.32%) HPLC Purity: (RT: 3.333 min, Purity: 97.32%)1H NMR (400 MHz, MeOD) δ: 8.01-7.98 (m, 2H), 7.56-7.53 (m, 2H), 3.94 (s, 2H), 3.66 (s, 2H), 3.59 (s, 2H), 3.53 (t, J= 16 Hz, 20 Hz, 2H), 3.25-3.18 (m, 6H), 3.0 (t, J= 16 Hz, 8 Hz, 1H), 2.44- 2.36 (m, 4H), 2.26 (s, 3H), 1.33 (t, J = 5.2 Hz, 12.4 Hz, 6H). Experimental protocol for Compounds 3 and 4: Step-1: Synthesis of benzyl 3-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3] heptane-6-carboxamido)azetidine-1-carboxylate: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylic acid KSM 2 (0.25 g, 0.72mmol) in DMF (10V, 2.5mL) was added HATU (0.41g, 1.01mmol) at room temperature. Then benzyl 3-aminoazetidine-1- carboxylate (0.16g, 0.72mmol) and DIPEA (0.27g, 2.10mmol) were added to reaction mixture. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, cold water (10 mL) was added to reaction mixture to obtain solid precipitates, which was filtered using Buckner funnel to solid get crude material and which was purified by flash column chromatography (product eluted at 77% of [10% MeOH in DCM with 0.1% NH4OH] in DCM) to get pure benzyl 3-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamido)azetidine-1-carboxylate (0.21g, 54.45% yield) as pale yellow sticky solid. LCMS [ESI, M, M+2]: 535.2, 537.3 (RT: 2.157min, Purity: 100.00%) Step-2: Synthesis of N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide (Compound 3) and N-(azetidin-3-yl)-2-((2-(4- chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 4): Procedure: To a stirred solution of benzyl 3-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamido)azetidine-1-carboxylate (0.1g, 0.18mmol) in MeOH (1mL, 10V) was added 10% Pd / C (0.03g, 30% w / w). The reaction mixture was purged with Nitrogen Attorney Docket No.063692-504001WO gas for 5 min. Then, H2was purged for 45 min at rt. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was diluted with MeOH (15 mL) and then filtered through celite bed and filtrate was evaporated under vacuum to get crude material, which was purified by Prep-HPLC purification to get pure N-(azetidin-3-yl)- 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamide Compound 4 (0.022g, 29.36% yield) and N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4- yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamide Compound 3 (0.035g, 51.10% yield) respectively both as a white sticky solid. Compound 4 LCMS [ESI, M, M+2]: 401.4, 403.4 (RT: 1.107min, Purity: 100.00%) HPLC Purity: (RT: 4.728min, Purity: 99.79%)1H NMR (400 MHz, D2O) δ: 8.03 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.8 Hz, 2H), 4.67-4.55 (m, 1H), 4.57 (s, 2H), 4.30-4.25 (m, 6H), 4.16-4.11 (m, 2H), 3.04-2.96 (m, 1H), 2.61-2.40 (m, 4H), 2.31 (s, 3H). Compound 3 LCMS [ESI, M+1]: 367.4 (RT: 1.005min, Purity: 100.00%) HPLC Purity: (RT: 4.153min, Purity: 100.00%)1H NMR (400 MHz, D2O) δ: 8.06-8.04 (m, 2H), 7.57-7.54 (m, 3H), 4.81-4.79 (m, 1H), 4.60- 4.55 (m, 1H), 4.57 (s, 2H), 4.30-4.25 (m, 5H), 4.20-4.10 (m, 2H), 3.01-2.96 (m, 1H), 2.61-2.40 (m, 4H), 2.32 (s, 3H). Experimental protocol for Compound 5: Attorney Docket No.063692-504001WO Step-1: Synthesis of N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3- yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 5): Procedure: To a stirred solution of N-(2-(diethylamino) ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate KSM 3 (0.62g, 2.6mmol) in MeOH (1.2mL, 10V) was added TEA (0.37g, 3.7mmol) at rt. After 10min, 2-methylimidazo[1,2-a]pyridine-3-carbaldehyde (0.12g, 0.74mmol) was added at room temperature and the reaction mixture was stirred at 85 °C for 24h. Then NaCNBH3 (0.094g, 1.49mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 850C for 6h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash chromatography 80% of (90:10:0.1%, DCM: MeOH: NH4OH) in DCM to get N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3- yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamide, Compound 5, (0.1g, 34.80% yield) as a yellow sticky liquid. LCMS Purity [ESI, M-1]: 382.3 (RT: 1.536 min, Purity: 96.41%) HPLC Purity: (RT: 4.184 min, Purity: 100%)1H NMR (400 MHz, MeOD) δ: 8.34 (d, J=8.00 Hz, 1H), 7.45 (d, J = 11.2 Hz, 1H), 7.33-7.29 (m, 1H), 6.95-6.91 (m, 1H), 3.91 (s, 2H), 3.36-3.32 (m, 2H), 3.28 (t, J = 14.4 Hz, 6.8 Hz, 2H), 3.23 (s, 2H), 2.95-2.86 (m, 1H), 2.63-2.59 (m, 6H), 2.46 (s, 3H), 2.32-2.29 (m, 4H), 1.07 (t, J=14.4 Hz, 7.2 Hz, 6H). Experimental protocol for Compound 6: Step-1: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- morpholinoethyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 6): Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl) methyl)-2-azaspiro [3.3] heptane-6-carboxylic acid (0.15 g, 0.43mmol) in DMF (10V, 1.5mL) was added HATU (0.24g, 0.64mmol) at room temperature. The reaction mixture was stirred at room temperature for 15 min. followed by added 2-morpholinoethan-1-amine (0.061g, 0.47mmol) and then after 10 min add DIPEA (0.16g, 1.29mmol) to reaction mixture. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, Reaction mixture was poured into water (40 mL) and product was extracted through EtOAc (3 x 30 mL). Combined organic layers were dried with Na2SO4 and evaporated under vacuum to get crude material, which was purified by Prep-HPLC purification to get pure 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- morpholinoethyl)-2-azaspiro[3.3]heptane-6-carboxamide Compound 6 (0.015g, 7.56% yield) as an off white sticky liquid. LCMS [ESI, M, M+2]: 459.4, 461.5 (RT: 1.807min, Purity: 100.00%) HPLC Purity: (RT: 5.095min, Purity: 97.68%)1H NMR (400 MHz, D2O) δ: 7.62 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.8 Hz, 2H), 3.58 (t, J = 9.2 Hz, 4.4 Hz, 4H), 3.45-3.43 (m, 2H), 3.20-3.16 (m, 4H), 3.06 (s, 2H), 2.86-2.78 (m, 1H), 2.39-2.33 (m, 6H), 2.19-2.04 (m, 4H), 1.99 (s, 3H). Experimental protocol for Compound 7: Step-1: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1- yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 7): Procedure: To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl) methyl)-2-azaspiro [3.3] heptane-6-carboxylic acid (0.45 g, 1.29mmol) in DMF (10V, 4.5mL), was added HATU (0.74g, 1.94mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 Attorney Docket No.063692-504001WO mins. Then added 2-(pyrrolidin-1-yl) ethan-1-amine (0.177g, 1.50mmol) followed by after 15 min was added DIPEA (0.50g, 3.80mmol) to the reaction mixture. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, Reaction mixture was poured into water (50 mL) and product was extracted through EtOAc (3 x 40 mL). Combined organic layers were dried with Na2SO4and evaporated under vacuum to get crude material, which was purified by Prep-HPLC purification to get pure 2-((2-(4-chlorophenyl)-5- methyloxazol-4-yl) methyl)-N-(2-(pyrrolidin-1-yl) ethyl)-2-azaspiro [3.3] heptane-6- carboxamide Compound 7 (0.09g, 15.66% yield) a yellow sticky solid. LCMS [ESI, M, M+2]: 443.4, 445.4 (RT: 1.788min, Purity: 100.00%) HPLC Purity: (RT: 6.905min, Purity: 100.00%)1H NMR (400 MHz, D2O) δ: 7.77 (d, J = 8.8 Hz, 2H), 7.42 (d, J = 8.8 Hz, 2H), 3.57 (s, 2H), 3.32- 3.30 (m, 4H), 3.18 (s, 2H), 2.95-2.80 (m, 7H), 2.24-2.12 (m, 4H), 2.05 (s, 3H), 1.80 (s, 4H). Experimental protocol for Compound 8: Step-1: Synthesis of tert-butyl (2-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3] heptane-6-carboxamido)ethyl)(ethyl)carbamate: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylic acid (0.45 g, 1.29mmol) in DMF (10V, 4.5mL) was added HATU (0.74g, 1.94mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 min. Then tert-butyl (2-aminoethyl)(ethyl)carbamate (0.29g, 1.50mmol) and then after 10 min DIPEA (0.50g, 3.80mmol) was added to reaction mixture. Reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis. Reaction mixture was poured into water (100 mL) and product was extracted by EtOAc (3 x 90 mL). Organic layer was dried with Na2SO4 and evaporated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 7% MeOH in DCM) to get pure tert-butyl (2-(2-((2-(4-chlorophenyl)-5-methyloxazol-4- yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamido)ethyl) (ethyl)carbamate (0.3g, 44.72% yield) as a white sticky solid. LCMS [ESI, M, M+2]: 517.4, 519.4 (RT: 2.124min, Purity: 84.80%) Step-2: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2-azaspiro[3.3]heptane-6-carboxamide dihydrochloride (Compound 8): Attorney Docket No.063692-504001WO Procedure: To a stirred solution of tert-butyl (2-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamido)ethyl)(ethyl)carbamate (0.3g, 0.58mmol) in DCM (3mL, 10V) was added 4M HCl in Dioxane (1.5mL, 4V) at 0°C. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was evaporated under vacuum to get crude material, which was purified by Prep HPLC to get pure 2-((2-(4-chlorophenyl)-5-methyloxazol- 4-yl)methyl)-N-(2-(ethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide dihydrochloride, Compound 8, (0.124g, 51.26% yield) as a white sticky solid. LCMS [ESI, M, M+2]: 417.0, 418.5 (RT: 1.330min, Purity: 100.00%) HPLC Purity: (RT: 6.042min, Purity: 100.00%)1H NMR (400 MHz, D2O) δ: 7.66 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.8 Hz, 2H), 3.50 (s, 2H), 3.33 - 3.25 (m, 4H), 3.14 (s, 2H), 2.92 - 2.89 (m, 1H), 2.84 (t, J = 12.4 Hz, 6.4 Hz, 2H), 2.77 (q, J = 21.6 Hz, 7.2 Hz, 2H), 2.23 - 2.11 (m, 4H), 2.00 (s, 3H), 1.05 (t, J = 14.8 Hz, 7.2 Hz, 3H). Experimental protocol for Compound 9: Step-1: Synthesis of 3-(4-chlorophenyl)-1,2,4-oxadiazole-5-carbaldehyde: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of (3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methanol (0.3g, 1.42mmol) in DCM (3mL, 10V) was added DMP (3.01g, 7.12mmol) at rt. The resulting reaction mixture was stirred at room temperature for 2h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was quenched with sat. NaHCO3solution (15mL), then filtered through celite. Filtrate was added water (40mL) and extracted with DCM (30mL). Organic layer were dried over Na2SO4, filtered and concentrate under vacuum to get 3-(4- chlorophenyl)-1,2,4-oxadiazole-5-carbaldehyde (0.3g, quantitative yield) as a yellow solid. Crude material was directly used for the next step reaction. Step-2: Synthesis of 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2- (diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 9): Procedure: To a stirred solution of N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (0.34g, 1.43mmol) in MeOH (3mL, 10V) was added TEA (0.58g, 5.75mmol) at 0°C. After 15min, 3-(4- chlorophenyl)-1,2,4-oxadiazole-5-carbaldehyde (0.3g, 1.3mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 2h. Then NaCNBH3 (0.18g, 2.87mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 800C for 14h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by prep-HPLC purification to get 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5- yl)methyl)-N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (0.042g, 7.57% yield) as a yellow sticky solid. LCMS Purity [ESI, M, M+2]: 432.0, 433.9 (RT: 0.920 min, Purity: 96.21%) HPLC Purity: (RT: 4.601 min, Purity: 96.70%)1H NMR (400 MHz, MeOD) δ: 8.11–8.08 (m, 2H), 7.61–7.58 (m, 2H), 5.00 (s, 2H), 4.50 (s, 4H), 3.55 (t, J=6.4 Hz, 2H), 3.32–3.26 (m, 6H), 3.06–3.02 (m, 1H), 2.65-2.59 (m, 2H), 2.58-2.50 Attorney Docket No.063692-504001WO (m, 2H), 1.36-1.30 (t, 6H). Experimental protocol for Compound 10: Step-1: Synthesis of tert-butyl 3-cyano-3-((2-(diethylamino)ethyl)carbamoyl)azetidine-1- carboxylate: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 1-(tert-butoxycarbonyl)-3-cyanoazetidine-3-carboxylic acid (0.3g, 1.32mmol) in DMF (3mL, 10V) was added HATU (0.75g, 1.98mmol) at rt. After 15min, N1,N1- diethylethane-1,2-diamine (0.14g, 1.32mmol) was added at room temperature and stirred for 15min, then DIPEA (0.51g. 3.90mmol) was added at rt. The resulting reaction mixture was stirred at room temperature for 2h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured into cold water (100mL) and extracted with EtOAc (2 X 100mL). Combine the organic layer was dried over Na2SO4, filtered and concentrated under vacuum to get tert-butyl 3-cyano-3-((2- (diethylamino)ethyl)carbamoyl)azetidine-1-carboxylate (0.43g, 99.95% yield) as a yellow sticky solid. Crude material was directly used for the next step. Mass [ESI, M+1]: 325.4, 326.4 Step-2: Synthesis of 3-cyano-N-(2-(diethylamino)ethyl)azetidine-3-carboxamide: Procedure: To a stirred solution of tert-butyl 3-cyano-3-((2-(diethylamino)ethyl)carbamoyl)azetidine-1- carboxylate (0.43g,1.32mmol) in DCM (4.3mL, 10V) was added TFA (2.15mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by trituration using diethyl ether to get 3- cyano-N-(2-(diethylamino)ethyl)azetidine-3-carboxamide (0.44g, Quantitative yield) as a yellow sticky solid. Mass [ESI, M+, M+2]: 225.3, 226.3 1H NMR (400 MHz, MeOD): δ 4.53 (q, J = 20.4, 11.2 Hz, 4H), 3.69 (t, J = 6.8 Hz, 2H), 3.37 - 3.32 (m, 3H), 3.04 - 3.01 (m, 1H), 2.88 - 2.83 (m, 2H), 1.40 - 1.34 (m, 6H). Step-3: Synthesis of 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide (Compound 10): Attorney Docket No.063692-504001WO Procedure: To a stirred solution 3-cyano-N-(2-(diethylamino)ethyl)azetidine-3-carboxamide TFA (0.4g, 1.78mmol) in MeOH (4mL, 10V) was added TEA (0.72g, 7.13mmol) at rt. After 15min, 2-(4- chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.39g, 1.78mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 5h. Then NaCNBH3(0.22g, 3.56mmol) was added at room temperature and the resulting reaction mixture was stirred at room temperature for 16h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by prep HPLC to get 1-((2-(4-chlorophenyl)-5-methyloxazol-4- yl)methyl)-3-cyano-N-(2-(diethylamino)ethyl) azetidine-3-carboxamide (0.12g, 15.86% yield) as white solid. LCMS Purity [ESI, M, M+2]: 430.1, 432.0 (RT:1.199 min, Purity: 100%) HPLC Purity: (RT: 4.910min, Purity: 100%)1H NMR (400 MHz, MeOD) δ: 7.85 (d, J = 8.8 Hz, 2H), 7.47 (d, J = 8.8Hz, 2H), 4.50 (d, J = 11.2, 2H), 4.42 (d, J = 6.8Hz, 4H), 3.49 (t, J = 13.2, 2H), 3.17 - 3.07 (m, 6H), 2.17 (s, 3H), 1.13 (t, J = 14.4, 6H). Experimental protocol for Compound 11:

[0003] Attorney Docket No.063692-504001WO Step-1: Synthesis of tert-butyl 3-(2-((2-(diethylamino)ethyl)amino)-2-oxoethyl)azetidine-1- carboxylate: Procedure: To a stirred solution of 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid (1.0g, 4.6mmol) in DMF (10mL, 10V) was added HATU (2.6g, 6.9mmol) at rt. After 30 min, N1, N1-diethylethane- 1,2-diamine (0.53g, 4.6mmol) at rt. After 15min, DIPEA (1.80g, 1.3mmol) was added at room temperature and the resulting reaction mixture was stirred at room temperature for 2h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured into cold water (80mL) and extracted with EtOAc (3 X 60mL). Attorney Docket No.063692-504001WO Combine organic layer was washed with cold water (2 X 100mL) and dried over Na2SO4, filtered and concentrated under vacuum to get tert-butyl 3-(2-((2-(diethylamino)ethyl)amino)- 2-oxoethyl)azetidine-1-carboxylate (0.3g, 68.67% yield) as a brown sticky solid. Crude material was directly used for the next step. LCMS Purity [ESI, M+1]: 314.3 (RT: 1.621 min, Purity: 67.13%) Step-2: Synthesis of 2-(azetidin-3-yl)-N-(2-(diethylamino)ethyl)acetamide: Procedure: To a stirred solution of tert-butyl 3-(2-((2-(diethylamino)ethyl)amino)-2-oxoethyl)azetidine-1- carboxylate (0.7g, 2.2mmol) in DCM (7mL, 10V) was added TFA (3.5mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by trituration using diethyl ether (2 x 20mL) to get 2-(azetidin-3-yl)-N-(2-(diethylamino)ethyl)acetamide (0.6g, quantitative yield) as a yellow sticky solid.1H NMR (400 MHz, MeOD) δ: 4.16 (t, J=11.2Hz, 2H), 3.95 (t, J= 8.00Hz, 2H), 3.55 (t, J= 8.00Hz, 2H), 3.50-3.39 (m, 1H), 3.32-3.27 (m, 6H), 2.67 (t, J=7.6 Hz, 2H), 1.34(t, J=7.2 Hz, 6H). Step-3: Synthesis of 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N- (2-(diethylamino)ethyl)acetamide: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of 2-(azetidin-3-yl)-N-(2-(diethylamino)ethyl)acetamide (0.7g, 3.2mmol) in MeOH (7mL, 10V) was added TEA (1.33g, 13.14mmol) at 0°C. After 15min, 2-(4- chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.72g, 3.2mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 5h. Then NaCNBH3(0.41g, mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at room temperature for 16h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was poured into water (40 mL) and product was extracted with 10% MeOH in DCM (2 X 25mL). Combined organic layers were dried with Na2SO4 and concentrated under vacuum to get crude material, which was purified by prep HPLC purification to get 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2- (diethylamino)ethyl) acetamide (0.15g, 11.34% yield) as a pale yellow solid. LCMS [ESI, M, M+2]: 419.1, 421.1 (RT: 1.050 min, Purity: 98.49%) HPLC Purity: RT: 3.649 min, Purity: 97.73%)1H NMR (400 MHz, MeOD) δ: 8.04-8.01 (m, 2H), 7.58-7.55 (m, 2H), 4.63 (s, 2H), 4.40-4.25 (m, 2H), 4.15 (t, J=8.4 Hz, 2H), 3.55 (t, J=6.4 Hz, 2H), 3.36 (s, 2H), 3.30-3.25 (m, 5H), 2.80- 2.60 (m,2H), 2.32 (s, 3H), 1.33 (t, J=7.2 Hz, 6H). Experimental protocol for Compound 12:

[0004] Attorney Docket No.063692-504001WO Step-1: Synthesis of tert-butyl 3-((2-(diethylamino)ethyl)carbamoyl)-3-fluoroazetidine-1- carboxylate: Procedure: To a stirred solution of 1-(tert-butoxycarbonyl)-3-fluoroazetidine-3-carboxylic acid (0.3g, 1.36mmol) in DMF (3mL, 10V) ware added HATU (0.78g, 2.05mmol) at rt. After 30min, N1, N1-diethylethane-1,2-diamine (0.17g, 1.50mmol) was added and stirred for 15min. Then DIPEA (0.53g, 4.1mmol) was added at room temperature and the resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and Mass analysis. After completion of reaction, the reaction mixture was poured in cold water (70mL) and extracted with EtOAc (3 X 50mL). Combine organic layer was dried over Na2SO4, filtered and concentrated under vacuum to get crude material, which was purified by flash column Attorney Docket No.063692-504001WO chromatography (product eluted at 4% MeOH in DCM) to get tert-butyl 3-((2- (diethylamino)ethyl)carbamoyl)-3-fluoroazetidine-1-carboxylate (0.32g,73.67% yield) as a pale yellow sticky solid.1H NMR (400 MHz, MeOD) δ: 4.39-4.31 (m, 2H), 4.14–4.06 (m, 2H), 3.44 (t, J=6.9 Hz, 2H), 2.77 (bs, 6H), 1.47 (s, 9H), 1.14 (t, J=7.2 Hz, 6H). Step-2: Synthesis of N-(2-(diethylamino)ethyl)-3-fluoroazetidine-3-carboxamide 2,2,2- trifluoroacetate: Procedure: To a stirred solution of tert-butyl 3-((2-(diethylamino)ethyl)carbamoyl)-3-fluoroazetidine-1- carboxylate (0.22g, 0.63mmol) in DCM (2.2mL, 10V) was added TFA (1.1mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by trituration using diethyl ether: pentane (1:1, 15mL x 2) to get N-(2-(diethylamino)ethyl)-3-fluoroazetidine-3-carboxamide 2,2,2- trifluoroacetate(0.18g, quantitative yield) as a yellow solid.1H NMR (400 MHz, MeOD) δ: 4.62-4.55 (m, 2H), 4.45–4.37 (m, 2H), 3.67 (t, J=6.4 Hz, 2H), 3.36-3.32 (m, 6H), 1.35 (t, J=7.6 Hz, 6H). Step-3: Synthesis of 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- - Procedure: To a stirred solution of N-(2-(diethylamino)ethyl)-3-fluoroazetidine-3-carboxamide TFA (0.23g, Attorney Docket No.063692-504001WO 1.08mmol) in MeOH (2mL, 10V) was added TEA (0.36g, 3.60mmol) at 0°C. After 10min, 2-(4- chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.2g, 0.90mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 2h. Then NaCNBH3 (0.11g, 1.80mmol) was added at 0°C under N2atmosphere and the resulting reaction mixture was stirred at 800C for 14h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by reverse phase column chromatography (product eluted at 40% ACN in water) to get 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-3-fluoroazetidine-3-carboxamide Compound 12 (0.08g, 20.96% yield) as a yellow sticky solid. LCMS [ESI, M, M+2]: 423.0, 424.9 (RT: 1.003 min, Purity: 98.53%) HPLC Purity: (RT: 4.592 min, Purity: 100.0%)1H NMR (400 MHz, MeOD) δ: 7.99 (d, J=8.8 Hz, 2H), 7.53 (d, J=8.8 Hz, 2H), 3.90-3.82 (m, 4H), 3.72-3.64 (m, 2H), 3.40–3.34 (m, 2H), 2.65-2.59 (m, 6H), 2.26 (s, 3H), 1.07 (t, J=7.2 Hz, 6H). Experimental protocol for Compound 13: Attorney Docket No.063692-504001WO Step-1: Synthesis of tert-butyl 3-((2-(diethylamino)ethyl)carbamoyl)azetidine-1- carboxylate: Procedure: To a stirred solution of 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (0.3g, 1.49mmol) in DMF (3mL, 10V) was added HATU (0.85g, 2.23mmol) at rt. After 15min N1, N1-diethylethane- 1,2-diamine (0.17g, 1.49mmol) was added at room temperature and stirred for 20min. Then DIPEA (0.55g, 4.28mmol) was added at room temperature and the resulting reaction mixture was stirred at room temperature for 2h. Progress of the reaction was monitored by TLC and mass analysis. After completion of reaction, the reaction mixture was poured into cold water (100mL) and extracted with EtOAc (2 X 100mL). Combined organic layer was dried over Na2SO4, filtered and concentrated under vacuum to get tert-butyl 3-((2- (diethylamino)ethyl)carbamoyl)azetidine-1-carboxylate (0.5g, quantitative yield) as a yellow sticky solid. Crude material was directly used for next step. Mass [ESI, M+1]: 300.4 Step-2: Synthesis of N-(2-(diethylamino)ethyl)azetidine-3-carboxamide: Procedure: To a stirred solution of tert-butyl 3-((2-(diethylamino)ethyl)carbamoyl)azetidine-1-carboxylate (0.5g, 1.66mmol) in DCM (5mL, 10V) was added TFA (2.5mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get N-(2-(diethylamino)ethyl)azetidine-3-carboxamide (0.5g, quantitative yield) as a yellow solid. Crude material was directly used for the next step. Attorney Docket No.063692-504001WO Mass [ESI, M+1]: 200.3 Step-4: Synthesis of 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl) azetidine-3-carboxamide: Procedure: To a stirred solution of N-(2-(diethylamino)ethyl)azetidine-3-carboxamide (0.5g, 2.50mmol) in MeOH (5mL, 10V) was added TEA (1.01g, 10.03mmol) at rt. After 30min, 2-(4-chlorophenyl)- 5-methyloxazole-4-carbaldehyde (0.55g, 2.50mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 2h. Then NaCNBH3 (0.31g, 5.01mmol) was added at room temperature and the resulting reaction mixture was stirred at room temperature for 16h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash column chromatography [product eluted at 78% of MeOH: NH4OH: DCM (2:8:0.2) in DCM] to get 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide carboxamide (0.1g, 10.95% yield) as a white solid. LCMS Purity [ESI, M, M+2]: 405.1, 407.0 (RT: 0.949 min, Purity: 97.68%) HPLC Purity: RT: 4.435 min, Purity: 95.99% 1H NMR (400 MHz, MeOD) δ: 7.98 (d, J=8.8 Hz, 2H), 7.53 (d, J=8.8 Hz, 2H), 3.76 (s, 1H) 3.60 (t, J=8 Hz, 2H), 3.49 (t, J=7.6 Hz, 2H), 3.39 (t, J=6.8 Hz, 2H), 2.82 (bs, 6H), 2.25 (s, 3H), 1.15 (t, J=7.2Hz, 6H). Experimental protocol for Compound 14: Attorney Docket No.063692-504001WO Step-4: Synthesis of 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2- (diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 14): Procedure: To a stirred solution of N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate(0.51g, 2.10mmol) in MeOH (4mL, 10V) was added TEA (0.73g, 7.20mmol) at 0°C. After 10min, 3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazole-5-carbaldehyde (0.4g, 1.80mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 5h. Then NaCNBH3(0.22g, 3.60mmol) was added at room temperature and the resulting reaction mixture was stirred at 750C for 11h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was quenched with water (10mL), and concentrated under vacuum to get crude material, which was purified by flash column chromatography [product eluted at 75% of (10% MeOH in DCM with 0.1% of NH4OH) in DCM] to get 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2- (diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (0.25g, 31.13% yield) as a white solid. LCMS [ESI, M, M+2]: 445.1, 447.00 (RT: 1.085 min, Purity: 96.92%) HPLC Purity: (RT: 5.850 min, Purity: 100.00%)1H NMR (400 MHz, MeOD) δ: 7.99 (d, J=8.8 Hz, 2H), 7.46 (d, J=8.8 Hz, 2H), 3.94 (s, 3H), 3.80 (s, 2H), 3.44 (s, 2H), 3.35 (s, 2H), 3.32–3.24 (m, 2H), 2.95-2.91 (m, 1H), 2.64–2.57 (m, 6H), 2.35-2.33 (m, 4H), 1.08 (t, J=6.8 Hz, 6H). Experimental protocol for Compound 15: Attorney Docket No.063692-504001WO Step-1: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 15): Procedure: To a stirred solution of N-(2-(diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (0.86g, 3.60mmol) in MeOH (8mL, 10V) was added TEA (1.46g, 14.43mmol) at rt. After 10min, 2-(4- chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.8g, 3.60mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 2h. Then NaCNBH3 (0.45g, 7.21mmol) was added at 0°C under N2atmosphere and the resulting reaction mixture was stirred at 800C for 14h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash chromatography (95:5:0.3%, MeOH:NH4OH:DCM in DCM) to get 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)- 2-azaspiro[3.3]heptane-6-carboxamide (0.2g, 12.45% yield) as an yellow sticky solid. LCMS Purity [ESI, M, M+2]: 445.0, 446.8 (RT: 0.968 min, Purity: 97.67%) HPLC Purity: (RT: 3.622 min, Purity: 96.42%) 1H NMR (400 MHz, MeOD) δ: 7.98 (d, J=6.8 Hz, 2H), 7.55–7.52 (m, 2H), 3.70 (s, 2H), 3.44 (s, 2H), 3.38–3.34 (m, 2H), 3.30-3.26 (m, 2H), 2.95-2.91 (m, 1H), 2.64–2.57 (m, 6H), 2.34 (d, J=8.0 Hz, 4H), 2.24 (s, 3H), 1.07 (t, J=7.2 Hz, 6H). Experimental protocol for Compound 16: Attorney Docket No.063692-504001WO Step-1: Synthesis of 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1- yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 16): Procedure: To a stirred solution of N-(2-(pyrrolidin-1-yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2-trifluoroacetate(1.18g, 4.96mmol) in MeOH (2mL, 10V) was added TEA (2.76g, 19.9mmol) at 0°C. After 5 min, 2-methylimidazo[1,2-a]pyridine-3-carbaldehyde (0.2g, 1.24mmol) was added at room temperature and the reaction mixture was stirred at 85°C for 5h. Then NaCNBH3 (0.156g, 2.48mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 85°C for 16h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash column chromatography [product eluted at 95% (1% ammonia in MeOH) in DCM to get 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2- (pyrrolidin-1-yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (0.15g, 19.27% yield) as yellow Sticky solid. LCMS [ESI, M+1]: 382.5 (RT: 1.897min, Purity: 99.61%) HPLC Purity: (RT: 1.77min, Purity: 99.55%)1H NMR (400 MHz, MeOD) δ: 8.05 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 12.0 Hz, 1H), 7.24-7.20 (m, 1H), 6.85-3.81 (m, 1H), 3.78 (s, 2H), 3.22-3.16 (m, 4H), 3.10 (s, 2H), 2.85-2.77 (m, 1H), 2.52-2.46 (m, 6H), 2.28 (s, 3H), 2.19-2.07 (m, 4H), 1.63-1.62 (m, 4H). Experimental protocol for Compound 17: Attorney Docket No.063692-504001WO Step-1: Synthesis of tert-butyl 6-((1-ethylazetidin-3-yl)carbamoyl)-2-azaspiro[3.3]heptane- 2-carboxylate: Procedure: To a stirred solution of 2-(tert-butoxycarbonyl)-2-azaspiro[3.3]heptane-6-carboxylic acid (0.5 g, 2.07mmol) in DMF (10V, 5mL) was added HATU (1.181g, 3.11mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 mins. Then 1-ethylazetidin-3-amine (0.310g, 3.11mmol) and then after 10 min DIPEA (0.803g, 6.21mmol) was added to reaction mixture. Reaction mixture was stirred at room temperature for 1h. Progress of the reaction was Attorney Docket No.063692-504001WO monitored by TLC and LCMS analysis. After completion of reaction, reaction mixture was poured into water (100 mL) and product was extracted by EtOAc (3 x 60 mL). Organic layer was dried over Na2SO4 and evaporated under vacuum to get crude tert-butyl 6-((1-ethylazetidin-3- yl)carbamoyl)-2-azaspiro[3.3]heptane-2-carboxylate (1.0g, Quantitative yield) as a brown sticky solid. MASS [ESI, M+1]:324.4 Step-2: Synthesis of N-(1-ethylazetidin-3-yl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate: Procedure: To a stirred solution of tert-butyl 6-((1-ethylazetidin-3-yl)carbamoyl)-2-azaspiro[3.3]heptane-2- carboxylate (1.0g, 3.09mmol) in DCM (10mL, 10V) was added TFA (10mL, 5V) at 00C. The resulting reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get N-(1-ethylazetidin-3-yl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate (1.6g, Quantitative yield) as a brown sticky solid. MASS [ESI, M+1]: 224.2 Step-3: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin- - Procedure: To a stirred solution of N-(1-ethylazetidin-3-yl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2- trifluoroacetate(1.006g, 4.50 mmol) in MeOH (10mL, 20V) was added TEA (3.13g, 22.0mmol) Attorney Docket No.063692-504001WO at 0°C. After 5min, 2-(4-chlorophenyl)-5-methyloxazole-4-carbaldehyde (0.5g, 2.20mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 5h. Then NaCNBH3 (0.283g, 4.50mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 85°C for 16h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 90% MeOH in DCM) with ammonia as a modifier to get 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)- N-(1-ethylazetidin-3-yl)-2-azaspiro[3.3]heptane-6-carboxamide (0.05g, 5.17% yield) as light pink solid. LCMS [ESI, M, M+2]: 429.0, 431.0 (RT: 1.029min, Purity: 95.39%) HPLC Purity: (RT: 2.664min, Purity: 96.60%)1H NMR (400 MHz, MeOD) δ: 7.97 (d, J = 8.00Hz, 2H), 7.53 (d, J = 8.00 Hz, 2H), 4.41 (s, 1H), 3.69-3.67 (m, 2H) 3.66-3.64 (m, 2H), 3.42 (s, 2H), 3.33-3.31 (m, 2H), 2.95-2.89 (m, 3H), 2.55- 2.50 (m, 2H), 2.33-2.31 (m, 2H), 2.22 (s, 3H), 0.97 (t, J = 4.0 Hz, 12.0 Hz, 3H) Experimental protocol for Compound 18: Step-1: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-N-methyl-2-azaspiro[3.3]heptane-6-carboxamide: Procedure: To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (0.13g, 0.29mmol) in DMF (1.3mL, 10V) was added NaH (0.017g, 0.73mmol) at 0°C, stirred the reaction mixture for 15 min followed by added Methyl Iodide (0.49g, 0.35mmol) at room temperature and the reaction mixture was stirred at room temperature for 45 min. Progress of the reaction was monitored by Attorney Docket No.063692-504001WO TLC analysis. After completion of reaction, the reaction mixture was poured into water (30 mL) and product was extracted by EtOAc (2 x 20 mL), Organic layer was dried over sodium sulphate and evaporated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 10% of (MeOH in DCM) to get 2-((2-(4-chlorophenyl)-5- methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2-azaspiro[3.3]heptane-6- carboxamide (0.07g, 52.20% yield) as a pale yellow gummy solid. LCMS Purity [ESI, M, M+2]: 459.3, 461.3 (RT: 2.073 min, Purity: 99.25%) HPLC Purity: (RT: 8.630 min, Purity: 95.81%)1H NMR (400 MHz, DMSO) δ: 7.92 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.4 Hz, 2H), 3.58 (s, 2H), 3.33 (s, 1H), 3.28 (s, 3H), 2.50 (s, 2H), 2.46 (s, 3H), 2.17 (d, J = 10.8 Hz, 6H), 2.00 - 1.97 (m, 2H), 1.60 – 1.59 (m, 2H), 1.25 - 1.23 (m, 3H), 0.92 – 0.89 (m, 6H). Experimental protocol for Compound 19: Step-6: Synthesis of 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2- (pyrrolidin-1-yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 19): Procedure: To a stirred solution of N-(2-(pyrrolidin-1-yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide 2,2,2-trifluoroacetate(0.64g, 2.70mmol) in MeOH (6.4mL, 10V) was added TEA (1.36g, 13.53mmol) and stirred at room temperature for 10 min, followed by added 2-(4-chlorophenyl)- 5-methyloxazole-4-carbaldehyde (0.15g, 0.67mmol), the reaction mixture was stirred at room temperature for 16h. Then NaCNBH3 (0.085g, 1.35mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 850C for 3h. Progress of the reaction was monitored by TLC analysis. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash chromatography (95:5:0.3%, MeOH:NH4OH:DCM in DCM) to get 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4- triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide Attorney Docket No.063692-504001WO 9.21% yield) as an yellow sticky solid. LCMS Purity [ESI, M, M+2]: 443.1, 444.9 (RT: 1.135 min, Purity: 99.64%) HPLC Purity: (RT: 4.288min, Purity: 98.85%)1H NMR (400 MHz, D2O) δ: 7.74 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 3.78 (s, 3H), 3.71 (s, 2H), 3.37 (s, 2H), 3.40 - 3.35 (m, 4H), 2.89 (t, J = 8.4 Hz, 1H), 2.72 - 2.62 (m, 6H), 2.26 – 2.16 (m, 4H), 1.71 (s, 4H). Experimental protocol for Compound 20: Attorney Docket No.063692-504001WO Step-1: Synthesis of methyl 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)- 2-azaspiro[3.3]heptane-6-carboxylate: Procedure: To a stirred solution of methyl 2-azaspiro[3.3]heptane-6-carboxylate 2,2,2- trifluoroacetate(1.40g, 9.02mmol) in MeOH (14mL, 10V) was added TEA (4.56g, 45.11mmol) at 0°C. After stirred at 5min, 3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazole-5-carbaldehyde (0.5g, 2.25mmol) was added at rt. Reaction mixture was stirred at room temperature for 5h, then NaCNBH3(0.28g, 4.51mmol) was added at 0°C under N2atmosphere and the resulting reaction mixture was stirred at 85°C for 16h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash column chromatography (product was eluted at 5% MeOH in DCM) to get methyl 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylate (0.25g, 13.58% yield) as yellow sticky solid. LCMS [ESI, M, M+2]: 361.2, 363.2 (RT: 1.944 min, Purity: 91.22%) Step-2: Synthesis of 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-2- azaspiro [3.3]heptane-6-carboxylic acid: Procedure: To a stirred solution of methyl 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylate (0.25g, 0.69mmol) in MeOH (10V, 2.5mL) was added 2M Attorney Docket No.063692-504001WO NaOH (7V, 1.75mL) at rt. The reaction mixture was stirred at for 1 hour. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, the reaction mixture was evaporated under vacuum and then pH~4-5 was balanced with 1N HCl, then reaction mixture was lyophilized and diluted with 10% MeOH in DCM, which was evaporated under vacuum to get pure 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylic acid (0.2g, 83.24% yield) as yellow solid. LCMS [ESI, M, M+2]: 346.9, 348.7 (RT: 1.207min, Purity: 89.05%) Step-3: Synthesis of tert-butyl (2-(2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl) methyl)-2-azaspiro[3.3]heptane-6-carboxamido)ethyl)(ethyl)carbamate: Procedure: To a stirred solution of 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylic acid (0.2g, 0.57mmol) in DMF (10V, 2mL) was added HATU (0.32g, 0.86mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 mins. Then tert-butyl (2-aminoethyl)(ethyl)carbamate (0.13g, 0.69mmol) and then after 10 min was added DIPEA (0.22g, 1.72mmol) to reaction mixture. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured into water (50 mL) and product was extracted by EtOAc (3 x 30 mL). Organic layer was dried with Na2SO4 and evaporated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 3% MeOH in DCM) to get pure tert-butyl (2-(2-((3-(4-chlorophenyl)-1- methyl-1H-1,2,4-triazol-5-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamido)ethyl)(ethyl)carbamate (0.15g, 50.30% yield) as a yellow solid. LCMS [ESI, M, M+2]: 516.9, 519.2(RT: 2.082min, Purity: 79.38%) Step-4: Synthesis of 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2- (ethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide dihydrochloride (Compound 20): Attorney Docket No.063692-504001WO Procedure: To a stirred solution of tert-butyl (2-(2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5- yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamido)ethyl)(ethyl)carbamate (0.15g, 0.29mmol) in DCM (1.5mL, 10V) was added 4M HCl in Dioxane (0.75mL, 5V) at 0°C. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was evaporated under vacuum to get crude material, which was purified by reverse phase column chromatography (product eluted at 34% ACN in water) to get pure 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4- triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2-azaspiro[3.3]heptane-6-carboxamide dihydrochloride (0.07g, 57.87% yield) as a white sticky solid. LCMS [ESI, M, M+2]: 417.1, 419.0 (RT: 1.072min, Purity: 99.04%) HPLC Purity: (RT: 8.207min, Purity: 100.00%)1H NMR (400 MHz, D2O) δ: 7.82 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 4.59 (s, 2H), 4.34 (s, 2H), 4.26 (s, 2H), 3.83 (s, 3H), 3.39 (s, 3H), 3.05 (t, J = 6.0 Hz, 2H), 3.06 – 3.01 (m, 3H), 3.00 - 2.95 (m, 3H), 2.55 - 2.45 (m, 2H), 2.45 - 2.37 (m, 2H), 1.16 (t, J = 14.4 Hz, 3H). Experimental protocol for Compound 21:

[0005] Attorney Docket No.063692-504001WO Step-1: Synthesis of tert-butyl (S)-4-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carbonyl)-2-methylpiperazine-1-carboxylate: Procedure: To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptane-6-carboxylic acid (0.2g, 0.57mmol) in DMF (10V, 2 mL) was added HATU (0.32g, 0.86mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 min followed by added tert-butyl (S)-2-methylpiperazine-1-carboxylate (0.13g, 0.69mmol), stirred the reaction mixture for 10 min, then added DIPEA (0.22g, 1.72mmol) to the reaction mixture. The reaction mixture was stirred at room temperature for 45 mins. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, the reaction mixture was poured into water (30 mL) and product was extracted by EtOAc (2 x 25 mL). Organic layer was dried with Na2SO4 and evaporated under vacuum to get crude material, which was purified by flash column chromatography (product was eluted at 5% MeOH in DCM) to get Attorney Docket No.063692-504001WO pure tert-butyl (S)-4-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carbonyl)-2-methylpiperazine-1-carboxylate (0.15g, 49.16% yield) as a yellow sticky solid. LCMS [ESI, M, M+2]: 529.1, 530.8 (RT: 1.486min, Purity: 96.36%) Step-2: Synthesis of (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3] heptan-6-yl)(3-methylpiperazin-1-yl)methanone dihydrochloride (Compound 21): Procedure: To a stirred solution of tert-butyl (S)-4-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carbonyl)-2-methylpiperazine-1-carboxylate (0.15g, 0.28mmol) in DCM (1.5mL, 10V) was added 4M HCl in Dioxane (0.75mL, 5V) at 0 °C. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was evaporated under vacuum to get crude material, which was purified by Reverse phase column chromatography (product was eluted at 75% MeCN in Water ) to get pure (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4- yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3-methylpiperazin-1-yl)methanone dihydrochloride (0.038g, 31.25% yield) as a light yellow sticky solid. LCMS [ESI, M, M+2]: 429.0, 431.0 (RT: 1.074min, Purity: 100.00%) HPLC Purity: (RT: 9.165min, Purity: 95.33%) Chiral HPLC Purity: (RT: 6.820min, Purity: 97.54%) Instrument Name: Waters SFC Investigator with PDA detector Chromatographic separation was conducted with Waters SFC Investigator with PDA detector. The column used was CHIRAL ICT (250 x 4.6 mm; 5μm) and the compounds were eluted with, Mobile Phase A: Liquid CO2, Mobile Phase B: 0.1% Diethyl amine in Propane-2-ol:Acetonitrile(70:30); with Flow rate = 4 mL / min; with Column Oven Temperature 40° C; ABPR 100 bar, analysis time Attorney Docket No.063692-504001WO 12 min.1H NMR (400 MHz, D2O) δ: 7.74 (d, J = 7.6 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 4.20 - 4.10 (m, 1H), 3.80 - 3.70 (m, 2H), 3.61 - 3.59 (m, 1H), 3.50 (s, 2H), 3.36 (d, J = 6.0 Hz, 2H), 3.25 - 3.17 (m, 1H), 3.10 - 3.00 (m, 1H), 2.85 - 2.75 (m, 2H), 2.70 - 2.60 (m, 1H), 2.52 - 2.49 (m, 1H), 2.40 - 2.15 (m, 4H), 2.06 (s, 3H), 1.03 - 0.99 (m, 3H). Experimental protocol for Compound 22: Step-1: Synthesis of tert-butyl (R)-4-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carbonyl)-2-methylpiperazine-1-carboxylate: Procedure: To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptane-6-carboxylic acid (0.2 g, 0.57mmol) in DMF (10V, 2 mL) was added HATU (0.32g, Attorney Docket No.063692-504001WO 0.86mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 min followed by added tert-butyl (R)-2-methylpiperazine-1-carboxylate (0.13g, 0.69mmol), stirred for 10 min then added DIPEA (0.22g, 1.72mmol) to the reaction mixture. The reaction mixture was stirred at room temperature for 45 min. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured into water (30 mL) and product was extracted by EtOAc (2 x 25 mL). Organic layer was dried with Na2SO4 and evaporated under vacuum to get crude material, which was purified by flash column chromatography (product was eluted at 5% MeOH in DCM) to get pure tert-butyl (R)-4-(2-((2- (4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6-carbonyl)-2- methylpiperazine-1-carboxylate (0.15g, 49.16% yield) as a yellow solid. LCMS [ESI, M, M+2]: 529.1, 530.8 (RT: 1.477min, Purity: 94.05%) Step-2: Synthesis of (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3] heptan-6-yl)(3-methylpiperazin-1-yl)methanone dihydrochloride: Procedure: To a stirred solution of tert-butyl (R)-4-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptane-6-carbonyl)-2-methylpiperazine-1-carboxylate (0.15g, 0.28mmol) in DCM (1.5mL, 10V) was added 4M HCl in Dioxane (0.75mL, 5V) at 0 °C. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was evaporated under vacuum to get crude material, which was purified by Reverse phase column chromatography (product eluted at 50% ACN in Water) to get pure (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2- azaspiro[3.3]heptan-6-yl)(3-methylpiperazin-1-yl)methanone dihydrochloride (0.07g, 57.56% yield) as a white solid. LCMS [ESI, M, M+2]: 429.1, 430.9 (RT: 1.085min, Purity: 100.00%) HPLC Purity: (RT: 2.648min, Purity: 99.53%) Attorney Docket No.063692-504001WO Chiral HPLC Purity: (RT: 7.11min, Purity: 97.51%) Instrument Name: Waters SFC Investigator with PDA detector Chromatographic separation was conducted with Waters SFC Investigator with PDA detecto. The column used was CHIRAL ICT (250 x 4.6 mm; 5μm) and the compounds were eluted with, Mobile Phase A: Liquid CO2, Mobile Phase B: 0.1% Diethyl amine in Propane-2- ol:Acetonitrile(70:30); with Flow rate = 4 mL / min; with Column Oven Temperature 40° C; ABPR 100 bar, analysis time 12 min.1H NMR (400 MHz, D2O) δ: 7.83 (dd, J = 2.4, 8.8 Hz, 2H), 7.46 (d, J = 7.6 Hz, 2H), 4.39 - 4.32 (m, 2H), 4.10 (s, 2H), 4.00 - 3.95 (m, 2H), 3.65 - 3.59 (m, 1H), 3.45 - 3.20 (m, 3H), 3.20 - 3.10 (m, 1H), 3.09 - 2.90 (m, 2H), 2.85 - 2.70 (m, 1H), 2.45 - 2.30 (m, 4H), 2.10 (s, 3H), 1.19 - 1.13 (m, 3H). Experimental protocol for Compound 23: Attorney Docket No.063692-504001WO Step-1: Synthesis of methyl 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-azaspiro[3.3] heptane-6-carboxylate: Procedure: To a stirred solution of methyl 2-azaspiro[3.3]heptane-6-carboxylate 2,2,2- trifluoroacetate(0.38g, 2.49mmol) in MeOH (1mL, 10V) was added TEA (1.26g, 12.40mmol) at 0°C. After 5min, 2-methylimidazo[1,2-a]pyridine-3-carbaldehyde (0.1g, 0.62mmol) was added at 80°C for 24h, Then NaCNBH3 (0.078g, 1.24mmol) was added at 0°C under N2 atmosphere and the resulting reaction mixture was stirred at 80°C for 16h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was concentrated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 3% MeOH in DCM) to get 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylate (0.15g, 49.11% yield) as yellow solid. LCMS [ESI, M+1]: 300.2 (RT: 1.644 min, Purity: 75.93%) Step-3: Synthesis of 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxylic acid: Procedure: To a stirred solution of 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-azaspiro[3.3]heptane- 6-carboxylate (0.1g, 0.33mmol) in THF (10V, 1mL) was added 2M NaOH (5V, 0.7mL) at rt. The reaction mixture was stirred at for 1 hour. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, Reaction mixture was evaporated under Attorney Docket No.063692-504001WO vacuum and then pH was balanced to neutral with 1N HCl, reaction mixture was lyophilized and then diluted with 10% MeOH in DCM, which was evaporated under vacuum to get ((2- methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-azaspiro[3.3]heptane-6-carboxylic acid (0.1g, Quantitative yield) as yellow solid. LCMS [ESI, M+1]: 286.2 (RT: 1.197min, Purity: 79.98%) Step-4: Synthesis of tert-butyl ethyl(2-(2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamido)ethyl)carbamate: Procedure: To a stirred solution of ((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxylic acid (0.1g, 0.31mmol) in DMF (10V, 1mL), HATU (0.19g, 0.51mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 30 min followed by added tert-butyl (2-aminoethyl)(ethyl)carbamate (0.079g, 0.42mmol), stirred for 10 min then added DIPEA (0.13g, 1.00mmol) was added to reaction mixture. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis, after completion of reaction, the reaction mixture was poured into water (50 mL) and product was extracted by EtOAc (3 x 30 mL). Organic layer was dried with Na2SO4and evaporated under vacuum to get crude material, which was purified by flash column chromatography (product eluted at 8% MeOH in DCM) to get pure tert-butyl ethyl(2-(2-((2- methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamido)ethyl)carbamate (0.13g, 81.42% yield) as a yellow solid. LCMS [ESI, M+1]: 456.4 (RT: 1.684min, Purity: 100.00%) Step-5: Synthesis of N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3- yl)methyl)-2-azaspiro[3.3]heptane-6-carboxamide: Attorney Docket No.063692-504001WO Procedure: To a stirred solution of tert-butyl ethyl(2-(2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamido)ethyl)carbamate (0.2g, 0.43mmol) in DCM (2mL, 10V) was added 4M HCl in Dioxane (1mL, 4V) at 0 °C. The reaction mixture was stirred at room temperature for 1h. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was evaporated under vacuum to get crude material, which was purified by Prep. HPLC Purification (Ammonium Hydroxide) to get pure N-(2- (ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-azaspiro[3.3]heptane- 6-carboxamide (Compound 23) (0.03g, 19.22% yield) as a white sticky solid. LCMS [ESI, M+1]: 356.3 (RT: 4.558min, Purity: 99.48%) HPLC Purity: (RT: 4.558min, Purity: 99.48%)1H NMR (400 MHz, D2O) δ: 8.10 (d, J = 6.8 Hz, 1H), 7.38 (d, J = 9.2 Hz, 1H), 7.27 (t, J = 6.4 Hz, 1H), 6.88 (t, J = 6.0Hz, 1H), 3.83 (s, 2H), 3.26 (s, 2H), 3.21 (t, J = 6.4 Hz, 2H), 3.14 (s, 2H), 2.90 - 2.85 (m, 1H), 2.66 (t, J = 6.4 Hz, 2H), 2.58 (q, J = 14.4 Hz, 2H), 2.32 (s, 3H), 2.23 - 2.10 (m, 4H), 0.97 (t, J = 7.2 Hz, 3H). Experimental protocol for Compound 24: Step-4: Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1- yl)propyl)-2-azaspiro[3.3]heptane-6-carboxamide (Compound 24): Procedure: Attorney Docket No.063692-504001WO To a stirred solution of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptane-6-carboxylic acid (0.2g, 0.57mmol) in DMF (2mL, 10V) was added HATU (0.32g, 0.86mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 min. Then 3-(pyrrolidin-1-yl)propan-1-amine (0.09g, 0.69mmol) and then after 10 min DIPEA (0.22g, 1.72mmol) was added to reaction mixture. The reaction mixture was stirred at room temperature for 45 min. Progress of the reaction was monitored by TLC and LCMS analysis. After completion of reaction, the reaction mixture was poured into water (30 mL) and product was extracted by EtOAc (2 x 25 mL). Organic layer was dried with Na2SO4and evaporated under vacuum to get crude material, which was purified by reverse phase column chromatography (product was eluted at 30% ACN in Water) to get pure 2-((2-(4-chlorophenyl)- 5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2-azaspiro[3.3]heptane-6- carboxamide (0.05g, 18.97% yield) as a creamy sticky solid. LCMS [ESI, M, M+2]: 457.1, 458.9 (RT: 1.104min, Purity: 100.00%) HPLC Purity: (RT: 2.798min, Purity: 95.04%).1H NMR (400 MHz, D2O) δ: 7.74 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 3.76 (s, 2H), 3.62 - 3.50 (m, 3H), 3.41 (s, 2H), 3.23 - 3.19 (m, 2H), 3.12 (t, J = 13.2 Hz, 2H), 3.10 - 2.98 (m, 3H), 2.91 - 2.82 (m, 1H), 2.30 - 2.20 (m, 2H), 2.19 - 2.10 (m, 2H), 2.05 (s, 3H), 1.91 (bs, 4H). 1.81 - 1.73 (m, 2H). Experimental protocol for Compound 25: N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-cyanophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza- 6-spiro[3.3]heptanecarboxamide Attorney Docket No.063692-504001WO LCMS [ESI, M+1]: 434.1 (RT: 1.021min, Purity: 99.50%) HPLC: (RT: 3.968min, Purity: 99.32%) 1H NMR (400 MHz, d6-DMSO): δ 8.05 (d, J=8.4Hz, 2H), 7.97 (d, J=8.4Hz, 2H), 7.63 (t, J=11.6, 5.6Hz, 1H), 3.39 (s, 2H), 3.18 (s, 2H), 3.13-3.10 (m, 2H), 3.06 (s, 2H), 2.83-2.78 (m, 1H), 2.40-2.38 (m, 9H), 2.15-2.12 (m, 4H), 1.65-1.62(m, 4H). Experimental protocol for Compound 26: N-[2-(1-pyrrolidinyl)ethyl]-2-{[5-methyl-2-(p-tolyl)-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide LCMS [ESI, M+1]: 423.1 (RT: 1.100min, Purity: 100.00%) HPLC Purity: (RT: 3.542min, Purity: 97.95%) 1H NMR (400 MHz, d6-DMSO): δ 7.80 (d, J = 8.0 Hz, 2H), 7.64 (bs, 1H), 7.31 (d, J= 8.4 Hz, 2H), 3.53 (s, 2H), 3.21 (s, 2H), 3.14-3.09 (m, 4H), 2.80-2.78 (m, 1H), 2.41 (bs, 6H), 2.36 (s, 4H), 2.15-2.12 (m, 6H), 1.65 (bs, 4H). Experimental protocol for Compound 27: Attorney Docket No.063692-504001WO N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza- 6-spiro[3.3]heptanecarboxamide LCMS [ESI, M+1]: 427.1 (RT: 1.037 min, Purity: 100%) HPLC Purity: (RT: 4.313min, Purity: 98.98%) 1H NMR (400 MHz, d6-DMSO): δ 7.97-7.93 (m, 2H), 7.62 (t, J= 5.2Hz, 1H), 7.35 (t, J= 8.8Hz, 2H), 3.54 (s, 2H), 3.21 (s, 2H), 3.13-3.09 (m, 4H), 2.82-2.78 (m, 1H), 2.39-2.37 (m, 6H), 2.18- 2.07 (m, 7H), 1.64 (s, 4H). Experimental protocol for Compound 28: N-2-(diethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide LCMS [ESI, M, M+2]: 444.1, 445.9 (RT: 1.148 min, Purity: 100.00%) Attorney Docket No.063692-504001WO HPLC Purity: (RT: 4.151 min, Purity: 100.00%) 1H NMR (400 MHz, CD3OD): δ 8.38 (s, 1H), 7.76-7.72 (m, 2H), 7.54-7.50 (m, 2H), 4.30 (s, 2H), 4.19 (bs, 4H), 3.54 (t, J= 12.4 Hz, 6 Hz, 2H), 3.29-3.24 (m, 6H), 3.04-2.98 (m, 1H), 2.58- 2.54 (m, 4H), 2.39 (s, 3H), 1.33 (t, J= 14.4 Hz, 7.2 Hz, 6H). Experimental protocol for Compound 29: N-2-(diethylamino)ethyl(1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3- hydroxy-3-azetidinyl)acetamide LCMS [ESI, M, M+2]: 435.1,437.3 (RT: 1.067 min, Purity: 97.53%) HPLC Purity: (RT: 4.061 min, Purity: 99.50%) 1H NMR (400 MHz, d6-DMSO): δ 7.91 (d, J=8.4Hz, 2H), 7.75 (m, 1H), 7.58 (d, J=8.4Hz, 2H), 5.58 (bs, 1H), 3.64 (s, 2H), 3.36-3.33 (m, 2H), 3.09-3.08 (m, 2H), 3.01-2.99 (m, 2H), 2.45-2.36 (m, 8H), 2.15 (s, 3H), 0.90 (t, J= 7.2Hz, 6H). Experimental protocol for Compound 30:

[0006] Attorney Docket No.063692-504001WO N-[2-(1-pyrrolidinyl)ethyl]-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide LCMS [ESI, M, M+2]: 442.1, 443.9 (RT: 1.086 min, Purity: 100.00%) HPLC Purity: (RT: 4.266 min, Purity: 99.63%) 1H NMR (400 MHz, d6-DMSO): δ 8.32 (s, 1H), 8.17 (s, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.73 (m, 1H), 7.51 (d, J = 8.8 Hz, 2H), 3.49 (s, 2H), 3.31 (s, 2H), 3.22 (s, 2H), 3.19-3.14 (m, 2H), 2.82 (m, 1H), 2.58-2.54 (m, 6H), 2.20 -2.19 (m, 3H), 2.19 (s, 3H), 1.70 (bs, 4H). Experimental protocol for Compound 31: N-2-(ethylamino)ethyl-2-{[1-(p-chlorophenyl)-3-methyl-4-pyrazolyl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide Attorney Docket No.063692-504001WO LCMS [ESI, M, M+2]: 416.1, 417.8 (RT: 1.146 min, Purity: 96.92%) HPLC Purity: (RT: 4.199 min, Purity: 98.49%) 1H NMR (400 MHz, d6-DMSO): δ 10.86 (bs, 1H), 8.87 (bs, 2H), 8.66 (s, 1H), 8.20 (t, J= 11.2 Hz, 5.6 Hz, 1H), 7.79 (d, J= 9.2 Hz, 2H), 7.57 (d, J= 8.8 Hz, 2H), 4.18 (d, J= 5.6 Hz, 2H), 4.07-4.00 (m, 4H), 3.35-3.31 (m, 2H), 2.93-2.84 (m, 5H), 2.46-2.41 (m, 1H), 2.35-2.28 (m, 6H), 1.18 (t, J= 14.4 Hz, 7.2 Hz, 3H). Experimental protocol for Compound 32: N-[2-(1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza- 6-spiro[3.3]heptanecarboxamide LCMS [ESI, M, M+2]: 443.2, 445.2 (RT: 1.481 min, Purity: 100.00%) HPLC Purity: (RT: 4.079 min, Purity: 97.65%) 1H NMR (400 MHz, d6-DMSO): δ 7.91 (d, J = 8.4 Hz, 2H), 7.64-7.57 (m, 3H), 3.54 (s, 2H), 3.21 (s, 2H), 3.13 - 3.10 (m, 4H), 2.82-2.78 (m, 1H), 2.40-2.37 (m, 6H), 2.16-2.12 (m, 7H), 1.64 (bs, 4H). Experimental protocol for Compound 33: Attorney Docket No.063692-504001WO N-2-(ethylamino)ethyl-2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide LCMS [ESI, M, M+2]: 417.1, 418.6 (RT: 1.081 min, Purity: 100.00%) HPLC Purity: (RT: 4.63 min, Purity: 98.42%) 1H NMR (400 MHz, d6-DMSO): δ 7.91 (d, J = 8.8 Hz, 2H), 7.65-7.64 (m, 1H), 7.58 (d, J = 8.8 Hz, 2H), 3.55 (s, 2H), 3.34 (s, 2H), 3.13 (s, 2H), 3.13-3.05 (m, 2H), 2.83-2.79 (m, 1H), 2.16-2.10 (m, 7H), 1.86-1.78 (m, 2H), 0.97 (t, J = 7.2 Hz, 4H). Experimental protocol for Compound 34: N-[2-(2,2,2-trifluoroethylamino)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide Attorney Docket No.063692-504001WO LCMS [ESI, M, M+2]: 471.3, 473.3 (RT: 1.601 min, Purity: 98.91%) HPLC Purity: (RT: 5.37 min, Purity: 97.89%) 1H NMR (400 MHz, CD3OD): δ 8.00 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.8 Hz, 2H), 4.03 (s, 2H), 3.74-3.70 (m, 4H), 3.28-3.19 (m, 4H), 2.97-2.93 (m, 1H), 2.79 (t, J = 6.3 Hz, 2H), 2.44- 2.35 (m, 4H), 2.27 (s, 3H). Experimental protocol for Compound 35: N-[2-(3,3-difluoro-1-pyrrolidinyl)ethyl]-2-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4- yl]methyl}-2-aza-6-spiro[3.3]heptanecarboxamide LCMS [ESI, M+1]: 479.2, 481.1 (RT: 1.110 min, Purity: 100%) HPLC Purity: (RT: 4.203 min, Purity: 100%) 1H NMR (400 MHz, d6-DMSO): δ 7.91 (d, J=8.4Hz, 2H), 7.67 (t, J=5.6Hz, 1H), 7.58 (d, J = 8.8Hz, 2H), 3.54 (s, 2H), 3.21 (s, 2H), 3.13-3.10 (m, 4H), 2.89-2.78 (m, 3H), 2.67 (t, J=6.8Hz, 2H), 2.43 (t, J=6.8Hz, 2H), 2.23-2.14 (m, 9H). Experimental protocol for Compound 36: Attorney Docket No.063692-504001WO N-2-(ethylamino)ethyl-2-{[2-(p-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide LCMS [ESI, M+1]: 401.1 (RT: 1.025 min, Purity: 100.00%) HPLC Purity: (RT: 3.776 min, Purity: 98.29%) 1H NMR (400 MHz, d6-DMSO): δ 11.24 (bs, 1H), 8.89 (bs, 2H), 8.21-8.19 (m, 1H), 8.05-8.02 (m, 2H), 7.41 (t, J= 17.6 Hz, 8.8 Hz, 1H), 4.53 (d, J= 5.2 Hz, 2H), 4.14-4.06 (m, 4H), 3.35- 3.31 (m, 2H), 2.92-2.83 (m, 5H), 2.50-2.42 (m, 1H), 2.35-2.23 (m, 6H), 1.18 (t, J= 14.4 Hz, 7.2 Hz, 3H). Experimental protocol for Compound 37: (2-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-2-aza-6-spiro[3.3]heptyl)[(S)-3- methyl-1-piperazinyl]methanone LCMS [ESI, M, M+2]: 429.1, 430.9 (RT: 1.082 min, Purity: 97.66%) HPLC Purity: (RT: 4.028 min, Purity: 97.25%) Chiral HPLC Purity: (RT: 2.750 min, Purity: 95.83%) Attorney Docket No.063692-504001WO 1H NMR (400 MHz, d6-DMSO): δ 11.46 (bs, 1H), 9.57-9.48 (m, 2H), 7.99 (d, J = 8.4Hz, 2H), 7.64 (d, J = 8.4Hz, 2H), 4.54 (d, J = 4.8Hz, 2H), 4.27-4.24 (m, 1H), 4.16 (bs, 2H), 4.08-3.99 (m, 2H), 3.75 (s, 1H), 3.34-3.07 (m, 5H), 2.88-2.78 (m, 2H), 2.45-2.32 (m, 3H), 2.28-2.24 (m, 3H), 1.23 (d, J = 6.0Hz, 3H). Experimental protocol for Compound 38: {2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-2-aza-6-spiro[3.3]heptyl}[(S)-3-methyl-1- piperazinyl]methanone LCMS [ESI, M+1]: 395.1 (RT: 0.962 min, Purity: 97.06%) HPLC Purity: RT: 3.868 min, Purity: 97.81% Chiral HPLC Purity: (RT: 2.753 min, Purity: 95.20%) 1H NMR (400 MHz, d6-DMSO): δ 11.38 (bs, 1H), 9.55-9.46 (m, 2H), 7.99 (bs, 2H), 7.56 (bs, 3H), 4.55-4.54 (m, 2H), 4.27-4.24 (m, 3H), 4.09-3.97 (m, 2H), 3.26-3.00 (m, 5H), 2.84-2.81 (m, 2H), 2.43-2.27 (m, 3H), 2.24 (m, 3H), 1.23-1.22 (m, 3H). Experimental protocol for Compound 39: Attorney Docket No.063692-504001WO N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide LCMS [ESI, M, M+2]: 377.2, 379.2 (RT: 1.537 min, Purity: 98.37%) HPLC Purity: (RT: 5.218 min, Purity: 95.77%) 1H NMR (400 MHz, d6-DMSO): δ 11.41-11.03 (m, 1H), 8.93 (bs, 2H), 8.63-8.62 (m, 1H), 7.99 (d, J= 8.4 Hz, 2H), 7.62 (d, J= 8.4 Hz, 2H), 4.65 (s, 2H), 4.27-4.21 (m, 4H), 3.54 (s, 1H), 3.41-3.38 (m, 2H), 2.94 (bs, 4H), 2.26 (s, 3H), 1.21 (t, J= 7.2 Hz, 2H). Experimental protocol for Compound 40: N-[2-(1-pyrrolidinyl)ethyl]-1-{[2-(p-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methyl}-3- azetidinecarboxamide LCMS [ESI, M, M+2]: 403.4, 405.4 (RT: 5.186 min, Purity: 97.44%) HPLC Purity: (RT: 5.597 min, Purity: 98.50%) 1H NMR (400 MHz, d6-DMSO): δ 7.92 (d, J= 8.4 Hz, 2H), 7.83 (s, 1H), 7.58 (t, J= 8.4 Hz, Attorney Docket No.063692-504001WO 2H), 3.59 (s, 2H), 3.40-3.33 (m, 3H), 3.23-3.11 (m, 5H), 2.50 (bs, 4H), 2.15 (s, 3H), 1.67 (s, 4H). Experimental protocol for Compound 41: N-2-(ethylamino)ethyl-2-{[4-(p-chlorophenyl)-5-methyl-1,3-oxazol-2-yl]methyl}-2-aza-6- spiro[3.3]heptanecarboxamide LCMS [ESI, M, M+2]: 417.3, 419.3 (RT: 1.531 min, Purity: 95.97%) HPLC Purity: (RT: 5.927 min, Purity: 95.62%) 1H NMR (400 MHz, d6-DMSO): δ 11.35 (s, 1H), 8.96 (s, 2H), 8.23 (d, J= 5.6 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 4.60 (bs, 2H), 4.20 (d, J = 16.0 Hz, 3H), 3.34 (bs, 2H), 2.92-2.84 (m, 5H), 2.57 (d, J = 8.0 Hz, 3H), 2.33 (bs, 5H), 1.192 (t, J = 7.2 Hz, 3H). Experimental protocol for Compound 42:

[0007] Attorney Docket No.063692-504001WO N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-3- azetidinecarboxamide LCMS [ESI, M, M+2]: 377.3, 379.3 (RT: 1.436 min, Purity: 100.00%) HPLC Purity: (RT: 4.154 min, Purity: 97.24%) 1H NMR (400 MHz, d6-DMSO): δ 11.47-11.05 (m, 1H), 8.97 (m, 2H), 8.66-8.63 (m, 1H), 7.99 (d, J= 8.4 Hz, 2H), 7.63 (d, J= 8.0 Hz, 2H), 4.65 (s, 2H), 4.41-4.19 (m, 4H), 3.57-3.38 (m, 3H), 2.96-2.94 (m, 4H), 2.25 (s, 3H), 1.20 (t, J= 7.2 Hz, 3H). Experimental protocol for Compound 43: N-2-(ethylamino)ethyl-1-{[2-(p-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl}-3- azetidinecarboxamide LCMS [ESI, M, M+2]: 377.3, 379.3 (RT: 1.490 min, Purity: 100.00%) HPLC Purity: (RT: 4.283 min, Purity: 98.56%) Attorney Docket No.063692-504001WO 1H NMR (400 MHz, d6-DMSO): δ 11.35-11.00 (m, 1H), 8.90 (s, 2H), 8.61 (s, 1H), 7.98 (d, J = 7.6 Hz, 2H), 7.63 (d, J = 8.4 Hz, 2H), 4.60 (s, 2H), 4.24 (bs, 4H), 3.55 (t, J = 7.6 Hz, 1H), 3.34 (m, 2H), 2.95 (d, J = 6.0 Hz, 4H), 2.41 (s, 3 H), 1.20 (t, J = 7.2 Hz, 3H). Experimental protocol for Compound 44: N-2-(ethylamino)ethyl-6-{[2-(p-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-2,6-diaza- 2-spiro[3.3]heptanecarboxamide LCMS [ESI, M, M+2]: 418.1, 419.9 (RT: 1.082 min, Purity: 100.00%) HPLC Purity: (RT: 4.052 min, Purity: 100%) 1H NMR (400 MHz, d6-DMSO): δ 10.55 (s, 1H), 8.34 (s, 2H), 7.98 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 6.69 (s, 1H), 4.59 (bs, 2H), 4.33-4.30 (m, 4H), 3.97 (d, J = 35.6 Hz, 4H), 3.25-3.20 (m, 2H), 2.98-2.86 (m, 4H), 2.23 (s, 3H), 1.16 (t, J = 7.2 Hz, 3H). Experimental protocol for Compound 45: N-2-(diethylamino)ethyl-1-[(2-methyl-1,3a-diaza-3-indenyl)methyl]-4- piperidinecarboxamide LCMS [ESI, M+1]: 372.4 (RT: 1.534 min, Purity: 97.59%) Attorney Docket No.063692-504001WO HPLC Purity: (RT: 4.616 min, Purity: 96.52%)1H NMR (400 MHz, CD3OD) δ: 8.40 (d, J = 6.8 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.33-7.29 (m, 1H), 6.95-6.91 (td, 1H), 3.82 (s, 2H), 3.36-3.322 (m, 2H), 3.01-2.88 (m, 2H), 2.83-2.75 (m, 6H), 2.41 (s, 3H), 2.24–2.17 (m, 1H), 2.20-2.07 (td, 2H), 1.85–1.78 (m, 2H), 1.75–1.64 (m, 2H), 1.14 (t, J = 7.2 Hz, 6H). General experimental protocol for salt breaking The salts of the compounds of the present invention are converted into the free base of the compounds of the present invention as follows. The hydrochloride or dihydrochloride salt of a compounds of the present invention was added to water (10V). The reaction mixture was cooled to 5-10°C and basified using 2N K2CO3solution (3.3V) till pH above 8.0, then the desired product was extracted with EtOAc (3 x 10V). All organic extracts were combined and dried over Na2SO4, solvent removed under vacuum to get crude, which was purified by reverse phase chromatography using water: Acetonitrile. Product was eluted at 30% water in acetonitrile. Fractions were collected and lyophilize it to get pure cream solid. Exemplary free base generation of compound 8 Synthesis of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide (Compound 8 free base): Procedure: 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl) methyl)-N-(2-(ethyl amino) ethyl)-2-azaspiro [3.3] heptane-6-carboxamide dihydrochloride (15.0g) was dissolved in water (150mL, 10V). The reaction mixture was cooled to 5-10°C and basified using 2N K2CO3 solution (50mL, 3.3V) till pH above 8.0, then the desired product was extracted in ethyl acetate (3 x 10V). All organic phases were combined and dried over Na2SO4, distilled out to get crude product, which was Attorney Docket No.063692-504001WO purified by reverse phase chromatography using water: acetonitrile. Product was eluted at 30% water in acetonitrile. Fractions were collected and lyophilized to get pure 2-((2-(4- chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide (8.5g, 56.67%) as cream solid.1H NMR (400 MHz, DMSO-d6): δ: 7.91 (d, J = 8.8 Hz, 2H), 7.62 – 7.56 (m, 3H), 3.549 (s, 2H), 3.21 (s, 2H), 3.09 – 3.04 (m, 4H), 2.80 (t, J = 8.0 Hz, 1H), 2.49 – 2.45 (m, 3H), 2.19 – 2.10 (m, 7H), 0.96 (t, J = 7.2 Hz, 3H). LCMS [ESI, M, M+2]: 417.3, 419.2 (RT: 1.491min, Purity: 100.00%) HPLC Purity: (RT: 4.125min, Purity: 100%) Abbreviations TLC – Thin Layer Chromatography LCMS - Liquid chromatography mass spectrometry HPLC – High-performance liquid chromatography DMP – Dess-Martin Periodanne EtOAc – Ethyl acetate DMF – N,N-Dimethylformamide DIPEA – N,N-Diethylamine TEA - Triethylamine RT – Retention Time Rt – Room temperature NMR – Nuclear Magnetic Resonance DCM - Dichloromethane THF - Tetrahydrofuran KSM – Key Starting Material TFA – Trifluoroacetic acid CAN - Acetonitrile LAH – Lithium Aluminium Hydride min - minutes h - hours ESI – Electron Spray Ionisation CDI – Carbonyl Diimidazole SFC – Supercritical Fluid Chromatography Attorney Docket No.063692-504001WO Table 1: Compounds 1 to 24 and 25 to 45 of the present application. Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Attorney Docket No.063692-504001WO Biological assays and data As stated above, the compounds of the present invention induce and / or stimulate autophagy and are useful in treating autophagy-related diseases. The biological activity of the compounds of the present invention can be determined by any appropriate test to determine the ability to induce and / or stimulate autophagy Assessment of stimulation of autophagy Tandem reporter assay (assay to assess autophagic flux) Selected compounds of this invention were assessed for their ability to stimulate autophagy using a U2OS cell line stabling expressing RFP-eGFP-hLC3b (a tandem reporter cell line). During the process of autophagy, the cargo to be degraded is first enveloped by organelles called autophagosomes. These autophagosomes then fuse with lysosomes, causing Attorney Docket No.063692-504001WO them to become acidified and their digestive enzymes to become activated. The term “autophagic flux” is used to represent the dynamic process of autophagy: autophagic flux refers to the whole process of autophagy, including autophagosome formation, maturation, fusion with lysosomes, subsequent breakdown, and the release of macromolecules back into the cytosol (Zhang XJ, Chen S, Huang KX, Le WD. Why should autophagic flux be assessed? Acta Pharmacol Sin. 2013 May; 34(5): 595-9. doi: 10.1038 / aps.2012.184. Epub 2013 Mar 11). Compounds that stimulate autophagic flux stimulate the dynamic process of autophagy (the whole process of autophagy). LC3b is a protein found in the membrane of autophagosomes which has been used to generate genetic reporters of autophagy in cells. In these systems a tandem fusion of LC3b is engineered with two fluorescent proteins of different wavelengths: one which is acid sensitive (for example eGFP, which fluoresces green) and the other which is acid insensitive (for example RFP, which fluoresces red). Cells expressing RFP-eGFP-hLC3b can be examined using fluorescent microscopy: the autophagosomes present will fluoresce in both channels (either yellow in an overlay of both channels or puncta that are present in both the individual red and green channels) but the autolysosomes present will fluoresce in the RFP (red) channel only. Using a fluorescent microscope, the number of autophagosomes and autolysosomes can be counted, allowing for the monitoring of both the induction of autophagy (total puncta count) and the rate of autophagic flux (ratio of red-only to red-and-green puncta). The influence of small molecules on autophagy induction and flux can be assessed using this system by comparison to a non-treated control. Representative Procedure: Human osteosarcoma U2OS cells stably expressing RFP- eGFP-hLC3b were seeded (10,000 cells / well) into a 96-well glass-bottom plate (Cell Carrier Ultra, Perkin Elmer) in DMEM Glutamax media (Gibco) supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics (100 u / ml penicillin, 100 µg / ml streptomycin, Invitrogen), then incubated overnight in a humified atmosphere at 37 °C and 5% CO2. The cells were then treated with the compounds of interest, dissolved in DMSO, in a duplicated 5- or 10-point dose- response. 8 wells were treated with an equivalent volume of DMSO, 4 with 0.3 µM torin-1 as a positive control (MCE) and 4 wells with 0.4 µM torin-1 plus 0.2 µM bafilomycin (MCE) as a control for flux inhibition. The cells were returned to the incubator and the treatment continued for 24 hours. After treatment, the media was aspirated off and the cells fixed with a solution of 4% formaldehyde + 1% glutaraldehyde (Sigma) in dPBS (plus magnesium and calcium, Gibco). Fixation was allowed to proceed for 15 minutes at room temperature then the fixative solution discarded and replaced with PBS (Gibco) plus Hoescht 33342 (1 µg / ml, Sigma). After 30 Attorney Docket No.063692-504001WO minutes the plates were imaged on an Opera Phenix confocal microscope (Perkin-Elmer) using a 40x water objective, collecting using DAPI, mCherry and GFP channels. Cells were detected based upon the staining of their nuclei with DAPI using the Harmony image analysis software (Perkin-Elmer) and the number of autophagosomes (GFP and RFP puncta) and autolysosomes (RFP only puncta) per cell were counted using the spot picking function within the software. Compounds of this invention showed an increase in the number of RFP-only puncta (autolysosomes) relative to a DMSO-treated control (non-treated control) at 1 uM. This is evidence for significant stimulation of autophagic flux (and thus the whole process of autophagy) by the compounds of this invention, and particularly by these compounds under the conditions as tested. Table 2 shows this data for selected compounds. Compounds having an activity designated as “+” provided a 10% and 30% increase in activity (based on the number of RFP- only puncta (autolysosomes)) as a percentage of the DMSO treated control (non-treated control). Compounds having an activity designated as “++” provided between 30% and 50% increase in activity (based on the number of RFP-only puncta (autolysosomes)) as a percentage of the DMSO treated control (non-treated control). Compounds having an activity designated as “+++” provided between 50% and 100% increase in activity (based on the number of RFP-only puncta (autolysosomes)) as a percentage of the DMSO treated control (non-treated control). Compounds having an activity designated as “++++” provided above 100% increase in activity (based on the number of RFP-only puncta (autolysosomes)) as a percentage of the DMSO treated control (non- treated control). Table 2: Change in the number of RFP-only puncta (autolysosomes) relative to a DMSO- treated control (non-treated control) in a U2OS cell line stabling expressing RFP-eGFP-hLC3b (a tandem reporter cell line) Table 2 Attorney Docket No.063692-504001WO Activity in a mouse model of Charcot-Marie-Tooth 1A (CMT1A) Compound 45 was selected as an example compound of this invention to be evaluated in this model. This model (run by In vivex SAS, France) uses C3-PMP22 transgenic mice (B6.Cg- Tg(PMP22)C3Fbas / J) which express three copies of a wild-type human peripheral myelin protein 22 (PMP22) gene. These mice present an age-dependent demyelinating neuropathy characterized by predominantly distal loss of strength and sensation. C3-PMP mice show no overt clinical signs at 3 weeks and develop mild neuromuscular impairment in an age-dependent manner. They have stable, low nerve conduction velocities similar to adults with human CMT1A. Myelination is delayed in these mice, and they contain reduced numbers of myelinated Attorney Docket No.063692-504001WO fibers at 3 weeks of age. Overview of the study Animal characteristics: Sex / Species / Strain: B6.Cg-Tg(PMP22)C3Fbas / J Male Age: 3 weeks old Supplier: Jackson Laboratory (USA) Approximate weight at initiation of treatment: 18.0 g ± 2.5 g Animal number: 6 mice per group Animal identification: At the beginning of the study, animals were identified with a number on the tail. Each parameter was noted in the lab book. Acclimation and clinical signs: Animals arrived on site 7 days (one week) before the experiment to allow optimal acclimation. Clinical signs and mortality were recorded daily. Body weight was determined twice a week. Study outline: Dose: 30 mg / kg, twice a day Administration: Oral gavage Readouts: i) Rotarod (neuromuscular performance) ii) Sciatic nerve electrophysiology (EMG) iii) Histology of sciatic nerve Experimental time duration: Readouts measures at 1 and 2 months old. - Baseline rotarod and EMG readouts at 1 month old - Rotarod and EMG readouts at 2 months old - Western blot for PMP22 and histopathology of sciatic nerve at 2 months old Vehicle used for test compound 45: 5% DMSO in water (v / v) Vehicle control group: C3-PMP22 transgenic mice (CMT1a mice) treated with vehicle only ((5% DMSO in water (v / v)) Wild type control group: wild type mice treated with vehicle only ((5% DMSO in water (v / v)) Statistics: Statistical analyses were performed using Prism software. A probability less than 5% (p<0.05) was considered as significant. Attorney Docket No.063692-504001WO Operating procedures for study readouts Sciatic nerve electrophysiology. Electromyography was performed on mice anesthetized with ketamine / xylazine mixture. A pair of steel needle electrodes (AD Instruments, MLA1302) were placed subcutaneously along the nerve at the sciatic notch (proximal stimulation). A second pair of electrodes were placed along the tibial nerve above the ankle (distal stimulation). Supramaximal square-wave pulses, lasting 10 ms at 1 mA were delivered using a PowerLab 26T (AD Instruments). Compound muscle action potential (CMAP) was recorded from the intrinsic foot muscles using steel electrodes. Both amplitudes and latencies of CMAP were determined. The distance between the 2 sites of stimulation was measured alongside the skin surface with fully extended legs, and nerve conduction velocities (NCVs) were calculated automatically from sciatic nerve latency measurements using Excel. Rotarod. A rotating rod apparatus (Bioseb, France) was used to measure neuromuscular coordination and balance. Mice were first given a pretraining trial to familiarize them with the rotating rod. Latency to fall was measured at a successively increased speed from 4 to 40 rpm over a 300-second max. time period. Each animal underwent 3 trials a day. For each day, values from the 3 trials were averaged for each animal, and then averaged for each group. Sciatic nerve toluidine blue staining After animal sacrifice, the right sciatic nerves of 3 mice / group were fixed for 20 minutes in situ with 4 % PFA and 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.3). Then, nerves were removed and post-fixed overnight in the same buffer. After washing for 30 minutes in 0.2 M PBS buffer, the samples were dehydrated using ethanol gradient solutions, and embedded in epoxy resin. Semithin cross sections were cut and stained with 0.5 % of toluidine blue + 1 % borax + 100 mL MilliQ water. The axonal diameter, number of myelinated axons and the myelin g-ratio were quantified using Image J g-ratio plugging. Summary of in vivo study phase: Day 1: From 8 AM to 11 AM Progressive behavioral test learning (rotarod test learning) was carried out one day before to start the in vivo part of the study. In order to reduce animal stress and anxiety due to the new environment, animals remained for 2 hours in the behavioral test room. Day 2: From 8 AM to 11 AM - Rotarod: Attorney Docket No.063692-504001WO Baseline neuromuscular performances were analyzed using a rotarod test. The values from 3 trials were averaged for each animal, and then averaged for each animal group. Day 2: From 11 AM to 1 PM - Electrophysiology (EMG): The animals were anesthetized using ketamine / xylazine mixture and sciatic nerve electrophysiology recording was performed. The compound muscle action potential (CMAP) was recorded from the intrinsic foot muscles using steel electrodes. Then, the nerve conduction velocities (NCVs) of each animal were calculated from sciatic nerve latency measurements. From Day 2 to Day 30: At 7 AM and at 7 PM Compound 45 was administrated by oral gavage twice a day to the members of one group of mice (compound treated group). Vehicle only was administrated by oral gavage twice a day to the members of another group of mice (vehicle control group). Day 29: From 8 AM to 11 AM Progressive behavioral test learning (rotarod test learning) was carried out. In order to reduce animal stress and anxiety due to the new environment, animals remained for 2 hours in the behavioral test room. Day 30: From 8 AM to 11 AM - Rotarod: Neuromuscular performances were analyzed using a rotarod test. The values from 3 trials were averaged for each animal, and then averaged for each animal group Day 30: From 11 AM to 1 PM - Electrophysiology (EMG): The animals were anesthetized using ketamine / xylazine mixture and sciatic nerve electrophysiology recording was performed. The CMAP was recorded from the intrinsic foot muscles using steel electrodes. Then, the NCVs of each animal were calculated from sciatic nerve latency measurements as stated before. Day 30: 2 PM – Terminal procedure, sciatic nerve sampling: After electrophysiology recording, mice were sacrificed by cervical dislocation. The sciatic nerves of all animals were samples for histological analysis. Attorney Docket No.063692-504001WO Results Mortality and body weight No mortality was observed during the study. No pathological clinical sign was observed during the study. No significant differences on body weight were observed between groups suggesting the absence of a systemic toxic effect of Compound 45 at the analyzed time points. Rotarod test. As expected, similar rotarod latencies were observed between the wild type control, vehicle control and compound 45 treated groups at baseline (1 month old). Neuromuscular impairment was observed at 2 months old in the vehicle control group characterized by a significant decrease of the rotarod latency compared to the wild type control group. The Compound 45 treated group presented a significant increase of the rotarod latency compared to the vehicle control group at 2 months (at 2 months old, a 168% increase in mean rotarod latency was observed in the Compound 45 treated group compared to the vehicle control group). These data suggest a protective effect of Compound 45 on the neuromuscular impairment induced by the CMT1A disorder when administrated twice a day during one month at 30 mg / kg. Sciatic nerve electrophysiology. Compound Muscle Action Potential (CMAP) Amplitude As expected, similar CMAP amplitudes were observed between the wild type control, vehicle control and compound 45 treated groups at the baseline (1 month old). Nerve conduction impairment was observed at 2 months old in the vehicle control group characterized by a significant decrease of the CMAP amplitude compared to the wild type control group. At 2 months old, the Compound 45 treated group presented a significant increase of the CMAP amplitude compared to the vehicle control group (at 2 months old, an 121 % increase in CMAP amplitude was observed in the Compound 45 treated group compared to the vehicle control group). These data suggest a protective effect of Compound 45 on the nerve conduction impairment induced by the CMT1A disorder when administrated twice a day during one month at 30 mg / kg. Moreover, because the CMAP amplitude is directly linked to the axonal activity, these results suggest that Compound 45 targets the axonopathy of the peripheral nervous system induced by CMT disorder. Attorney Docket No.063692-504001WO Nerve conduction velocity (NCV) As expected, similar nerve conduction velocities were observed between the wild type control, vehicle control and compound 45 treated groups at the baseline (1 month old). Sciatic nerve conduction impairment was observed at 2 months old in the vehicle control group characterized by a significant decrease of the nerve conduction velocity compared to the wild type control group. At 2 months old, an increase of the nerve conduction velocity was observed for the Compound 45 treated group compared to the vehicle control group (at 2 months old, a 193% increase in NCV was observed in the Compound 45 treated group compared to the vehicle control group). These data confirm a positive efficacy of the compound 45 on the nerve conduction impairment induced by the CMT1A disorder when administrated twice a day during one month at 30 mg / kg. Moreover, because the nerve conduction velocity is directly linked to the myelin functionality, these results suggest that compound 45 also targets (directly or indirectly) myelinating Schwann cells of the peripheral nervous system. Histology analysis of sciatic nerve Sciatic nerve toluidine blue staining was performed to determine the efficacy of Compound 45 from a histological point of view. As expected, a significant decrease of the number of axons and axonal diameter and an increase of myelin g-ratio was observed in the vehicle control group compared to the wild type control group, confirming the presence of the anticipated neurohistopathology. A significant increase of the number of axons and axonal diameter was observed after Compound 45 treatment compared to the vehicle control group: also, a significant decrease of myelin g-ratio was observed after Compound 45 treatment compared to the vehicle control group (at 2 months old there was a 106% increase in the number of myelinating axons and a 85% increase in the axonal diameter and a 24% decrease in the g-ratio in the Compound 45 treated group compared to the vehicle control group). These data confirm the functional efficacy data observed using the behavioral test and electrophysiological analysis, and suggest that Compound 45 targets axonal and myelin Schwann cell pathology induced by CMT disorder. Summary and conclusions As expected, neuromuscular and electrophysiological impairment, together with a decrease of the number of axons and axonal and myelin diameter were observed in the vehicle control group (transgenic CMT1a mice treated with vehicle alone) compared to the wild type control group. The Compound 45 treated group presented a significant increase in the rotarod latency, CMAP amplitude, nerve conduction velocity and the number of axons and axonal diameter compared to Attorney Docket No.063692-504001WO the vehicle control group at 2 months old. Also, a decrease in the myelin g-ratio was observed in the Compound 45 treated group compared to the vehicle control group at 2 months old. Taken together, this data confirms that Compound 45 presents a significant protective effect on the neuropathy induced by CMT disorder under these experimental conditions; the compound increases neuromuscular and electrophysiological performances, and has efficacy from a histological point of view, when administrated twice a day during 30 days at 30 mg / kg. This model functions as an in vivo model of Charcot-Marie-Tooth 1A (CMT1A). Activity (positive effects) in this model strongly supports that compounds provided herein are efficacious in the treatment of Charcot-Marie-Tooth 1A (CMT1A and other autophagy-related diseases or conditions. In particular, the present invention relates to the following preferred items. 1. A compound according to formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting of Attorney Docket No.063692-504001WO L is selected from the group consisting of X is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX; R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4-alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3. 2. The compound according to item 1, wherein B is selected from the group consisting of 3. The compound according to item 1 or 2, wherein Attorney Docket No.063692-504001WO B 4. The compound according to any one of items 1 to 3, wherein L is selected from the group consisting of 5. The compound according to any one of items 1 to 4, wherein L 6. The compound according to any one of items 1 to 5, wherein RNis H; R2, R3are independently of each other selected from H, and C1-C2-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX. 7. The compound according to any one of items 1 to 6, wherein A is a 5-membered fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9-membered fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or Attorney Docket No.063692-504001WO substituted with one or more, same or different substituents RX. 8. The compound according to any one of items 1 to 7, wherein RXis C1-alkyl, or phenyl, wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen; n is 2; m is 1. 9. The compound according to any one of items 1 to 8, wherein the compound is selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, Attorney Docket No.063692-504001WO 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, and 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- azaspiro[3.3]heptane-6-carboxamide. 10. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to any one of items 1 to 9 and optionally a pharmaceutically acceptable carrier, diluent or excipient. 11. A compound according to any one of items 1 to 9 or a pharmaceutical composition according to item 10 for use in medicine. 12. A compound according to any one of items 1 to 9 or a pharmaceutical composition according to item 10 for use in the treatment of an autophagy-related disease or condition. Attorney Docket No.063692-504001WO 13. The compound or the pharmaceutical composition for use according to item 12, wherein said autophagy-related disease or condition is selected from the group consisting of neurodegenerative diseases, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, systemic lupus erythematosus, epilepsy, cancer, liver diseases (e.g. nonalcoholic fatty liver disease (NAFLD)), a1 antitrypsin deficiency, Charcot Marie Tooth syndrome, Rett Syndrome, Sickle Cell disease, Wilson Disease, amyloidosis, Gaucher’s diseases, lysosomal and glycogen storage disorders (e.g., Glycogen Storage Disease type 1A (GSD1A)), cystic fibrosis; viral infection and diseases human cytomegalovirus (HCMV) infection, hepatitis B, human immunodeficiency virus infection, Zika virus infection, coronavirus infection, HCoV-229E, HCoV-NL63, betacoronavirus infection, such as HCoV-OC43, SARS-CoV-1, HCoV-HKU1, MERS-CoV or SARS-CoV-2, bacterial infections, metabolic disorders, diabetes, fibrosis, silicosis, diabetic retinopathy, glaucoma, cataracts, age-related macular degeneration, glomerulonephritis, glomerulosclerosis, wound healing disorders, Niemann-Pick type C (NPC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), muscular dystrophy, Duchenne muscular dystrophy, Limb-girdle muscular dystrophy, myopathy, myofibrillar myopathy, hereditary myopathy, diabetic cardiomyopathy, anti-inflammatory disorders, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, irritable bowel syndrome, Crohn’s disease, vascular disorders, stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, Behcet’s syndrome, giant cell arteritis, polymyalgia rheumatic, Wegener’s granulomatosis, Churg-Strauss syndrome, vasculitis, Henoch-Schonlein pruprua, Kawasaki disease, viral infection or replication, pox virus infection, herpes virus infection, asthma, allergic rhinitis, COPD, osteoporosis, organ transplant rejection, psoriasis, hypertrophic scarring (keloid formation), adhesion formations following general or gynecological surgery, lung fibrosis, liver fibrosis, kidney fibrosis, disorders caused by intracellular parasites, malaria, tuberculosis, neuropathic pain, post-operative phantom limb pain or postherpetic neuralgia, allergies, amyotrophic lateral sclerosis (ALS), antigen induced recall response, immune response suppression, muscle degeneration and atrophy, frailty in aging, spinal cord injury, and diseases and conditions involving misfolded and / or nonfolded proteins. 14. The compound or the pharmaceutical composition for use according to item 12 or 13, wherein said treatment comprises a combination of at least one compound according to any one of items 1 to 9 with at least one addition pharmaceutically active substance for said autophagy- related disease or condition. Attorney Docket No.063692-504001WO 15. Use of a compound according to any one of items 1 to 9 for stimulating autophagy in an in- vitro assay.

Claims

Attorney Docket No.063692-504001WO CLAIMS 1. A compound according to formula (I)or a salt, stereoisomer, tautomer or N-oxide thereof, wherein each substitutable carbon atom in the above compound of formula (I) is independently unsubstituted or substituted with one or more, same or different substituents selected from C1- C4-alkyl, wherein A is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9- or 10-membered saturated, partially or fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; B is selected from the group consisting ofL is selected from the group consisting ofX is a 4- to 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents RX;Attorney Docket No.063692-504001WO R1is H, CN, OH, halogen, or C1-C4-alkyl; R2, R3are independently of each other selected from H, C1-C4-haloalkyl and C1-C4-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; RNis H, or C1-C4-alkyl; RXis halogen, C1-C4-alkyl, phenyl, or a 5- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, CN, and C1-C4- alkyl, or two substituents form =O; n is 1, 2 or 3; and m is 1, 2 or 3.

2. The compound according to claim 1, wherein B is selected from the group consisting of3. The compound according to claim 1 or 2, wherein4. The compound according to any one of claims 1 to 3, wherein L is selected from the group consisting ofAttorney Docket No.063692-504001WO 5. The compound according to any one of claims 1 to 4, wherein L6. The compound according to any one of claims 1 to 5, wherein RNis H; R2, R3are independently of each other selected from H, and C1-C2-alkyl; or R2and R3together with the nitrogen atom to which they are attached form a 5-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N, and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX.

7. The compound according to any one of claims 1 to 6, wherein A is a 5-membered fully unsaturated or aromatic heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or is a 9-membered fully unsaturated or aromatic heterobicyclyl, wherein said heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon and heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX.

8. The compound according to any one of claims 1 to 7, wherein RXis C1-alkyl, or phenyl, wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen; n is 2; m is 1.Attorney Docket No.063692-504001WO 9. The compound according to any one of claims 1 to 8, wherein the compound is selected from the group consisting of 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2- (diethylamino)ethyl)-5-oxa-2-azaspiro[3.4]octane-6-carboxamide, 2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, N-(azetidin-3-yl)-2-((5-methyl-2-phenyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(azetidin-3-yl)-2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptane-6- carboxamide, N-(2-(diethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-morpholinoethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(ethylamino) ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, 2-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-3-cyano-N-(2- (diethylamino)ethyl)azetidine-3-carboxamide, 2-(1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)azetidin-3-yl)-N-(2-(diethylamino)ethyl) acetamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-3- fluoroazetidine-3-carboxamide, 1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)azetidine-3- carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(1-ethylazetidin-3-yl)-2-Attorney Docket No.063692-504001WO azaspiro[3.3]heptane-6-carboxamide, 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(2-(diethylamino)ethyl)-N-methyl-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide, 2-((3-(4-chlorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl)methyl)-N-(2-(ethylamino)ethyl)-2- azaspiro[3.3]heptane-6-carboxamide dihydrochloride, (S)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3] heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, (R)-(2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-2-azaspiro[3.3]heptan-6-yl)(3- methylpiperazin-1-yl)methanone dihydrochloride, N-(2-(ethylamino)ethyl)-2-((2-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2- azaspiro[3.3]heptane-6-carboxamide, and 2-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)-N-(3-(pyrrolidin-1-yl)propyl)-2- azaspiro[3.3]heptane-6-carboxamide.

10. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to any one of claims 1 to 9 and optionally a pharmaceutically acceptable carrier, diluent or excipient.

11. A compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10 for use in medicine.

12. A compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10 for use in the treatment of an autophagy-related disease or condition.

13. The compound or the pharmaceutical composition for use according to claim 12, wherein said autophagy-related disease or condition is selected from the group consisting of neurodegenerative diseases, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, systemic lupus erythematosus, epilepsy, cancer, liver diseases (e.g. nonalcoholic fatty liver disease (NAFLD)), a1 antitrypsin deficiency, Charcot Marie Tooth syndrome, Rett Syndrome, Sickle Cell disease, Wilson Disease, amyloidosis, Gaucher’s diseases, lysosomal and glycogen storage disorders (e.g., Glycogen Storage Disease type 1A (GSD1A)), cystic fibrosis; viral infection and diseases human cytomegalovirus (HCMV) infection, hepatitis B, humanAttorney Docket No.063692-504001WO immunodeficiency virus infection, Zika virus infection, coronavirus infection, HCoV-229E, HCoV-NL63, betacoronavirus infection, such as HCoV-OC43, SARS-CoV-1, HCoV-HKU1, MERS-CoV or SARS-CoV-2, bacterial infections, metabolic disorders, diabetes, fibrosis, silicosis, diabetic retinopathy, glaucoma, cataracts, age-related macular degeneration, glomerulonephritis, glomerulosclerosis, wound healing disorders, Niemann-Pick type C (NPC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), muscular dystrophy, Duchenne muscular dystrophy, Limb-girdle muscular dystrophy, myopathy, myofibrillar myopathy, hereditary myopathy, diabetic cardiomyopathy, anti-inflammatory disorders, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, irritable bowel syndrome, Crohn’s disease, vascular disorders, stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, Behcet’s syndrome, giant cell arteritis, polymyalgia rheumatic, Wegener’s granulomatosis, Churg-Strauss syndrome, vasculitis, Henoch-Schonlein pruprua, Kawasaki disease, viral infection or replication, pox virus infection, herpes virus infection, asthma, allergic rhinitis, COPD, osteoporosis, organ transplant rejection, psoriasis, hypertrophic scarring (keloid formation), adhesion formations following general or gynecological surgery, lung fibrosis, liver fibrosis, kidney fibrosis, disorders caused by intracellular parasites, malaria, tuberculosis, neuropathic pain, post-operative phantom limb pain or postherpetic neuralgia, allergies, amyotrophic lateral sclerosis (ALS), antigen induced recall response, immune response suppression, muscle degeneration and atrophy, frailty in aging, spinal cord injury, and diseases and conditions involving misfolded and / or nonfolded proteins.

14. The compound or the pharmaceutical composition for use according to claim 12 or 13, wherein said treatment comprises a combination of at least one compound according to any one of claims 1 to 9 with at least one addition pharmaceutically active substance for said autophagy- related disease or condition.

15. Use of a compound according to any one of claims 1 to 9 for stimulating autophagy in an in- vitro assay.

Images